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ABSTRACT 
Over the last decade, antiretroviral therapy (ART) has been rolled out in Ethiopia at a large 
scale. However, the outcome and aspects of drug resistance have been poorly studied at the 
national level. Also, the epidemic has been reported to be dominated by HIV-1 subtype C 
(HIV-1C), but this has not been verified at a nationwide level. In this thesis, I aimed at 
studying the outcome of ART and molecular epidemiology of HIV-1C drug resistance in 
Ethiopia using the first countrywide HIV-1 cohort. Data and plasma samples were collected 
from 874 adult and adolescent patients (age ≥ 14 years; 60% females), recruited from seven 
university hospitals during 2009 – 2011.  
In Paper I, by on-treatment (OT) and intention-to-treat (ITT) analyses we determined the rate 
of treatment failure at month 6 and 12. Four multivariable logistic regression models were 
developed to identify baseline predictors of treatment outcome. OT analysis identified 
treatment failure in 8% and 7%, whereas with ITT analysis the figures were 23% and 34% at 
month 6 and 12, respectively. Hence, our study indicated early death and lost to follow up 
(LTFU) as the main risk factors for poor treatment outcome. In addition to the well-known 
baseline factors of ART outcomes, study site was identified as a strong predictor of failure, 
where regional hospitals had higher proportions of treatment failure and LTFU as compared 
to a national tertiary level hospital in the capital city.  
In Paper II, we assessed surveillance drug resistance mutations (sDRM) in major and minor 
viral populations by population-based Sanger sequencing (PBSS) and next-generation 
sequencing (NGS). The short-term impact of sDRM on the outcome of ART was also 
assessed. NGS detected sDRM associated with reverse transcriptase inhibitors (RTIs) and 
protease inhibitors (PIs) more frequently than PBSS as well as major integrase strand transfer 
inhibitors (INSTIs) DRMs in minor viral variants. The baseline RTI-DRMs were associated 
with treatment failure at month 6 and 12.  
In Paper III, by genotypic analysis of the V3-loop of env, we described the HIV-1C 
molecular epidemiology and co-receptor tropism trend. The epidemic has been still found to 
be monophylogenetically dominated by CCR5-tropic HIV-1C even in patients with advanced 
immunodeficiency, although a slight increasing temporal trend was observed in CXCR4-
containing strains. 
In Paper IV, genotypic resistance testing (GRT) of the HIV-1 pol gene described acquired 
DRMs at month 6 and 12 and near-full length genome (NFLG) analysis assessed amino acid 
changes in the gag, pol, vif, vpr, tat, vpu, and nef genes in paired baseline and month 6 
samples of virologic failures. Broad major RTI- DRMs were detected in most failure patients. 
K65R, at a high rate, was identified only in TDF treated patients. The NFLG assay described 
all target regions of interest for HIVDR. 
In conclusion, early death and LTFU are major contributors for ART failure in Ethiopia 
rather than detectable viremia; the universal test and treat strategy could possibly improve the 
treatment outcome. There is a geographical variation in ART outcome, which calls the need 
for provision of more support at regional hospitals. HIV-1C still dominates 
monophylogenetically the epidemic in Ethiopia. PBSS reports a broad DRM, but 
underestimates prevalence of the transmitted drug resistance (TDR). NGS identifies an even 
higher rate of DRMs including in the minor viral variants. Our NFLG assay covers all 
relevant target genes and is an attractive cost-efficient alternative for HIVDR surveillance.  
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1 INTRODUCTION 
Human immunodeficiency virus (HIV), an etiologic agent of acquired immunodeficiency 
syndrome (AIDS), is a chronic retroviral infection. Since AIDS was first reported in 1981 in 
the United States [1], the HIV epidemic has affected lives of millions of people, largely in 
sub-Saharan Africa (sSA). Like most other sSA, Ethiopia has experienced a severe HIV 
epidemic and remains to be one of the highly affected countries in the region [2]. Since its 
estimated introduction into the country in 1970s, the epidemic in Ethiopia has been 
monophylogenetically dominated by HIV-1 subtype C (HIV-1C), which was first identified 
in this country [3]. Currently, HIV-1C accounts for around half of the world HIV epidemic 
[4].    
In response to the global HIV epidemic, antiretroviral therapy (ART) has become widely 
available worldwide including sSA countries, the hardest hit region by the epidemic. Since 
2005, ART has been rolled out at a large scale in Ethiopia [5]. Subsequently, a significant 
decline in the epidemic has been observed over the years along with a decline in the national 
prevalence [6, 7]. However, a high number of people are still living with the virus throughout 
the country [8].  
1.1 THE HIV PANDEMIC IN BRIEF 
HIV has spread more rapidly than most other disease causing agents in recent human history 
and it still remains to be one of the threats to human health and development [9]. Few years 
after the first AIDS cases with occurrence of Pneumocystis carinii (jiroveci) pneumonia 
(PCP) among previously healthy homosexual Americans were reported [1], studies identified 
retrovirus [human T-lymphotropic virus type III/lymphadenopathy- associated virus (HTLV-
III/LAV)] as the causative agent of AIDS [10, 11], which was later renamed as HIV [12].  
During the last three and half decades the epidemic has claimed more than 35 million human 
lives in addition to the 36.7 million people living with HIV (PLHIV) as of 2016 [13].  Of the 
36.7 million PLHIV worldwide, sSA accounted for nearly 70% (25.5 million). The UNAIDS 
reported that the eastern and southern Africa region alone harbor 19.4 million PLHIV. The 
report also showed that through 2010 to 2016, new HIV infections declined by 29% in this 
region, although the region accounted for 43% (790 000) of the 1.8 million new infections 
globally reported in the year 2016. During those years AIDS-related deaths also declined by 
42% in this region, but still 420 000 of the one million total global AIDS-related deaths in the 
year 2016 were from this region.  
1.2 ORIGIN AND SPREAD OF THE VIRUS  
Studies have shown that the two types of HIV, HIV-1 and HIV-2, have evolved from simian 
immunodeficiency viruses (SIV) through multiple cross-species zoonotic transmissions [14]. 
The initial zoonotic cross-species transmissions believed to have occurred in west and central 
Africa and the virus might have entered into the human population at least after the early 
1900s [15]. HIV-1 and HIV-2 evolved in humans via different pathways, where transmission 
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event involving SIVcpz from chimpanzees gave rise to HIV-1 in southeastern Cameroon [16] 
and another transmission event involving SIVsmm from sooty mangabey gave rise to HIV-2 
[16, 17].  
In addition to their evolutionary pathways, HIV-1 and HIV-2 have distinguished genomic 
organizations and both of them have already diversified into different subtypes [14, 16]. 
Although both types still co-circulate in West Africa, HIV-1 successfully spread throughout 
the world, whereas HIV-2 mainly remains there though limited number of cases are also 
reported from other parts of the world [18]. In addition, HIV-2 is less virulent characterised 
by much longer asymptomatic period, low plasma RNA load, slower CD4 cell decline, and 
cause lower mortality rate [19].   
On the other hand, since its initial transmission to the human population in Africa during the 
early 20th Century, HIV-1 has evolved genetically and phenotypically due to its high genetic 
variabilities through mutations and recombination [20]. Phylogenetic analyses divide HIV-1 
into four groups including group M (major), group O (outlier), group N (non-M, non-O), and 
group P (putative, a newly identified group) [21]. Group M, the pandemic, accounts for over 
90% of the infections, whereas groups O and N are restricted in west and central Africa, and 
are responsible only for small proportion of infections. Group P was identified from 
individuals who were originally from Cameroon [22].  
The HIV-1 M group comprises nine subtypes including A–D, F–H, J and K as well as several 
circulating recombinant forms (CRFs) and multiple unique recombinant forms (URFs) [23, 
24]. In addition, some subtypes, such as subtype A and subtype F, are subdivided further. 
Generally, the genetic variation between subtypes and within subtypes range from 25% to 
35% and 15% to 20%, respectively [22]. The subtypes A–D, subtype G, CRF 01_AE and 
CRF 02_AG account for over 90% of the global HIV epidemic [24]. Of them, HIV-1C 
represents for half of the global epidemic followed by subtype A (12%), subtype B (11%), 
CRF02_AG (8%), CRF01_AE (5%), subtype G (5%), and subtype D (2%) in descending 
order [4, 24].    
The group M subtypes have rapidly expanded within the western and central Africa with 
subsequent establishment of multiple epidemics worldwide [22]. Generally, subtype 
distribution varies widely across the globe, but the greatest diversity occurred in sSA. Central 
Africa harbors an extremely high diversity, where all known HIV subtypes, many CRFs and 
unique strains are circulating, reflecting the age of the epidemic in the region [20, 24, 25]. 
The global expansion of the different subtypes has been partly linked to the advent of some 
specific modes and routes of transmission in different parts of the world. For instance, 
intravenous drug uses led to rapid spread of CRF01_AE in southeast Asia during 1980s [26] 
and subtype A in east Europe and Russia in 1990s [27]. In parallel, subtype B transmission 
believed to occur among homosexual men in North America and Europe at 1980s and it has 
been the predominant subtype in  Europe,  North  America  and Australia [23]. On the other 
hand, HIV-1C appeared to have slowly emerged [22, 27]. 
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In addition, some studies have reported variation in the transmission efficiency of different 
subtypes. Indeed the difference in the epidemiology of the different HIV subtypes such as the 
rapid spread of HIV-1C in Africa and India could potentially be linked to the fact that this 
subtype has high viral load in the genital tract [28] as well as its efficient transmission in the 
heterosexual population than other subtypes [29].  
The HIV-1C, which was first isolated in Ethiopia in the late 1980s by Prof Sönnerborg group 
[3], is highly predominant in the southern African epidemics and the Indian subcontinent [20, 
23, 24, 30]. Phylogenetic analyses and historical inference also show the introduction of HIV-
1C into the southern American region including Brazil from several African countries 
including Ethiopia [31]. However, unlike other sSA countries, even the neighboring East 
African countries, the HIV-1C has monophylogenetically dominated in Ethiopia since its 
introduction into the country in the 1970s, although the reason remains to be explained [32]. 
1.3 THE HIV EPIDEMIC IN ETHIOPIA  
Like other sSA countries, Ethiopia has been experiencing a severe HIV epidemic [33]. 
Although Ethiopia still continues to be one of the most heavily affected countries, recent 
figures revealed that the incidence of HIV infection has significantly decreased over the years 
along with a decline in the national prevalence [6, 7, 34]. Yet, in 2017 about 740 000 PLHIV 
were estimated to live in the country, which corresponds to adult prevalence of 1.16% [8, 35]. 
HIV-1C has been claimed to dominate the epidemic in the country although no broad analysis 
of the whole country has been done. Within the Ethiopian HIV-1C, subclusters are leading 
the diversity into main C and C' (some literatures labeled respectively as C9 and C10) [4], 
which are co-circulating in the country [36, 37].  
1.3.1 How was HIV introduced and spread in Ethiopia? 
Although there is no firm evidence on when and how the HIV was introduced into Ethiopia, 
the first two HIV positive cases were identified through analysis of serum samples collected 
in 1984 [38] and subsequently the first clinically overt AIDS cases were diagnosed in 1986 
[39]. The first study, which was conducted with the aim of defining when HIV was 
introduced into Ethiopia, stratified the samples into four groups. In groups 1 and 2, which 
included over 900 sera from 1982 and 1983, no samples were found to be HIV positive, 
whereas out of the 267 sera collected from 1984 (group 3), two samples were found to be 
positive and declared as the first to be diagnosed in the country followed by other 13 positive 
patients in group 4 in which 528 patients had been sampled during 1985 – 1987 at Tikur 
Anbessa Specialised Hospital (TASH) [38].  
The virus is believed to have been introduced into the country at least a couple of years later 
than in most other sSA, but the feature of the epidemic generally resembles that of other 
eastern African countries [40]. The introduction of the virus into the country during the early 
stage of the epidemic could be considered as part of the transcontinental spread with 
movement of people in relation to refugees, military missions, entrance of non-governmental 
international organizations into the capital city, Addis Ababa [38, 40].  
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Although earlier studies failed to report from where the virus was introduced into Ethiopia, 
some reports with phylogenetic analysis claimed that the two HIV-1C clusters C and C'  
resembles to C9 from southern African (south Africa and Malawi) and C10 from other 
eastern African countries (Kenya, Djubuti, Burundi, and Uganda), respectively [4]. This 
could potentially demonstrate the fact that the two co-circulating subclusters of HIV-1C 
would have been introduced from other African countries through the transcontinental 
movement.   
Again, like most other African countries, the infection is predominantly acquired through 
heterosexual contacts and perinatal transmission [41]. Early studies showed a high HIV 
prevalence among commercial sex workers followed by long truck drivers and soldiers, who 
are claimed to be instrumental for the most majority of the transmission in the country [40]. 
During the early stage of the epidemic the country was in a devastating civil war, which 
might have fueled the spread of the infection because there were a large displacement and 
movement of people, particularly militias, along the major transport routes, where 
commercial sex work is available. Mother to child transmission (MTCT) also played a role to 
a certain extent in expanding the epidemic in the country [2].   
Even if the country has achieved promising progresses in preventing new HIV infections over 
the past decade with a decline in the national prevalence, still much remains to be done. For 
example, recent reports emphasised the need for sustainable efforts in preventing new 
infection among most-at-risk population (MARP) groups such as commercial sex workers, 
mobile population, seasonal farm workers, those working in constructions, as well as sero-
discordant couples who could potentially spread the virus [6].  
1.3.2 Factors influencing the HIV epidemic in Ethiopia 
In general, the epidemiology of HIV is greatly influenced by a number of socio-economic, 
cultural, political, and geographical factors. In Ethiopia the spread and distribution of HIV 
has also been hugely affected by these factors [41]. The EDHS 2011 report showed nearly 
twice higher adult prevalence among women compared to men (1.9% vs 1.0%), which could 
be due to several biological, socio-economical and socio-cultural factors that could negatively 
affect the capacities of women in protecting themselves from infection [42].  
In addition, less proportions of women have been shown to have sufficient knowledge 
towards HIV and AIDS than men [43-45], which could potentially lead women to 
disproportionally be affected by the virus. Traditionally arranged marriage practices with 
elder men increase risks of HIV infections for younger women through hindering their 
chances for open discussions on sexual relationship between the couples. Urban areas also 
have been shown to have seven folds higher prevalence as compared to rural areas in 
Ethiopia (4.2% vs 0.6%) [41] . 
In the early stages of the epidemic a lack of awareness among health service providers led to 
the multiple uses of inadequately sterilized or unsterilized hypodermics and to blood 
transfusions without screening for HIV. Such practices are believed to have substantially 
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contributed to the spread of the virus in Ethiopia [38]. Like in other sSA, changes in 
tendencies towards sexual behaviors, especially towards extramarital relations and also 
multiple marriages contributed noticeably to the epidemic in the country. Further, economic 
problems particularly among youth group of the society together with gender inequities could 
lead females to start commercial sex work, which potentially predominates the transmission 
dynamics in urban areas [40].  
HIV coinfection with tuberculosis (TB) is a major problem in sSA as the region hosts over 
three-fourths of the coinfection cases worldwide [46, 47]. Ethiopia is one of the 22 countries 
with high TB burden [47]. This has been associated with special diagnostic and therapeutic 
challenges among TB-HIV co-infected patients [48], which could have bilateral adverse 
effects in the epidemiology of the two public health important diseases. This could lead such 
patients to be diagnosed late with advanced diseases, even in the ART era. Studies also 
reported that most people diagnosed positive for HIV with severe diseases and low CD4 
count (mostly < 200 cells/μl) [48-50]. Hence, the HIV epidemic is not only influenced by the 
virus, but also by other disease causing agents.    
1.4  VIROLOGY OF HIV-1 
HIV is a retrovirus belonging to genus Lentivirus in the Retroviridae family, 
Orthoretrovirinae subfamily [51]. It infects and replicates in a range of CD4+ host cells 
through reverse transcription with high rates of mutations that lead to a very heterogenous 
viral population [52]. 
1.4.1 HIV-1 structure, genomic organization, and genetic diversity 
A mature HIV-1 measures about 100 nm in diameter and has a spherical shape. Its structure 
and genomic organization typically follow the retrovirus family that comprises a single 
stranded, positive sense ribonucleic acid (RNA) genome of approximately 9.7 kilobases (kb) 
[53]. The virus genome comprises nine genes, which encode 15 proteins as shown below in 
Figure 1. 
 
 
Figure 1. HIV-1 gene map. The rectangles represent open reading frames. The small number 
in the upper left corner of each rectangle indicates where the gene starts. Reference positions 
are based on HXB2 numbering system. Source: HIV Los Alamos Database, available at 
https://www.hiv.lanl.gov/content/sequence/HIV/MAP/landmark.html. 
The virus envelope is a lipid bilayer, which is derived from host cell membrane while the new 
virus particle buds [54, 55]. Each envelope subunit comprises noncovalently associated 
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glycoproteins (gp120 and gp41), which are used in the virus-cell attachment upon infection of 
the cell. Structurally, gp120 is divided into five loops of high genetic variability (V1–V5) 
interspersed with less variable/constant (C1–C5) domain. Hence, envelope is the most 
variable component of the virus. The V region’s variability may result the envelope 
functionality, which can be demonstrated by the third variable loop (V3) region. Changes in 
amino acid within the V3 region could affect the virus co-receptor usage. The high genetic 
variability in its envelope confers a complex antigenic diversity for the HIV-1 [55]. 
Although all are required for a successful viral replication, the nine HIV genes can be 
classified into three functional groups: three major genes (gag, pol and env) code for 
structural proteins and the enzymes while the remaining six genes code for regulatory 
proteins (tat and rev) and accessory proteins (vif, vpr, vpu and nef) [53]. The pol gene 
encodes for three enzymes necessary for viral replication: reverse transcriptase (RT), 
integrase (IN) and protease (PR) [56].  
1.4.2 HIV-1 life-cycle and pathogenesis  
Similar to other animal retroviruses, the life cycle of HIV-1 is a complex process that relies 
upon the transcription and translation machinery of its host cell. Seven steps occur in the HIV 
life cycle: binding, fusion, reverse transcription, integration, transcription, assembly, and 
budding [56, 57]. Binding occurs to the CD4 receptor and chemokine co-receptors (the virus 
co-receptor usage is briefly described below). The binding of gp120 to cell surface CD4 leads 
to the creation of a binding site for a chemokine receptor [56, 57]. This initiates 
conformational changes in the gp120-gp41 unit complex [57], which allows the virus to enter 
into the CD4 cell and release its genetic material into cytoplasm [56]. Then, viral RNA is 
retro-transcribed and the provirus integrates into the cellular genome; virus proteins 
synthesized, and finally the virus is assembled and budding occurs [56]. 
Once HIV enters host cells, it replicates very rapidly producing a viral burst that infects many 
CD4 cells and involves all lymphatic tissues. There is a rapid turnover of CD4 cells that 
ultimately leads to their destruction and to a change in lymphoid tissues that prevent immune 
responses [56]. As the number of CD4 cells decreases, the immune system becomes 
increasingly compromised. Following the acute HIV infection, most patients enter a 
prolonged, asymptomatic phase characterised by a progressive decline in the CD4 count. 
AIDS-defining opportunistic infections (OIs) and malignancies become increasingly common 
[56]. AIDS is defined by the occurrence of any of more than 20 OIs or HIV-related cancers. 
The most common manifestations of AIDS include TB, PCP, as well as debilitation weight 
loss, diarrhea, HIV dementia, Kaposi’s sarcoma and lymphomas [58].  
1.4.3 HIV-1 co-receptor tropism 
As described above, HIV-1 uses its gp120 to bind to and infect CD4
+
 cells. In order to 
facilitate its entry, the virus subsequently uses chemokine co-receptors additionally. There are 
three HIV-1 phenotypes depending on the virus ability to use different co-receptors, including 
R5-tropic (those using CCR5 chemokine receptor), X4-tropic (those using CXCR4 
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chemokine receptor), or dual-tropic (R5X4 variants using both CCR5 and CXCR4 
chemokine receptors) strains [59]. The dual-tropic variants further classified as dual-R (more 
efficiently uses the CCR5 than CXCR4) or dual-X (more efficiently uses CXCR4 than 
CCR5) [60].  
HIV-1 mainly targets primary T-cells and macrophages, but both CCR5 and CXCR4 co-
receptors are expressed on all relevant target cells for the virus including dendritic cells. The 
co-receptor specificity is one of the critical factors to determine the virus ability in depleting 
the CD4
+
 T-lymphocytes and pathogenesis, where a shift from CCR5 to CXCR4 usage is a 
common phenomenon at later stage of the disease [61]. In general, R5-tropic virus strains 
dominate the virus population during the primary infection [62]. Pure X4-tropic strains 
substantially contributes to the population at a more advanced stage of the disease [63]. 
Hence, the virus population usually contains a mixture of R5- and X4-tropic variants at later 
stage of the disease [64]. 
However, studies have revealed variations in the utilization of CCR5 and/or CXCR4 co-
receptors across different HIV-1 subtypes, mainly later in the course of infection [65]. For 
example, HIV-1 subtype B emerges to use CXCR4 in approximately 40%–50% of infected 
individuals and subsequent shift in the virus population with increasing X4-tropic strains [63, 
64]. On the other hand, only a limited number of X4-tropic strains of HIV-1C have been 
reported and R5-tropic strains dominate throughout the course of infection, including late 
stage at AIDS [32, 66]. 
In addition, although failing to clearly show how the tropism dynamics take place, studies 
have revealed a higher proportion of CXCR4 using strains among treatment experienced 
HIV-infected patients as compared to ART naïve individuals [67]. On top of a rapid CD4 cell 
count decline and enhanced pathogenesis, the emergence of X4-tropic strains have been 
shown to be associated with a poorer treatment response to ART [67, 68] and reduced 
survival time in untreated individuals [21, 69]. However, it is not clear whether X4-tropic 
strains are inherently responsible for the poor prognosis and inferior therapeutic response as 
the emergence of such variants is associated with advanced disease progression accompanied 
by rapid decline in CD4 cell count. 
A large number of studies have revealed that the V3 region of gp120 is a critical determinant 
of co-receptor usage of HIV-1, although other regions have also been implicated [70]. Even 
though, most available data are generated from HIV-1 subtype B isolates, variations in amino 
acids within the V3 loop strongly influence the co-receptor usage of the virus [71]. This 
suggests that amino acid changes at certain specific positions in the V3 region play the most 
important roles in the interaction of gp120 with the co-receptors.  
1.5 HIV TREATMENT AND MONITORING 
Through extensive scientific research activities towards combating the global epidemic a 
number of potent antiretrovirals (ARVs) have been discovered for the treatment of HIV-1, 
which have turned the infection into a chronic and manageable disease [72]. 
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1.5.1 Antiretroviral drugs 
Early monotherapeutic treatment strategies, which were used up until the mid-1990s, had a 
number of challenges including incomplete virologic suppression, resulting in the emergence 
of multiple drug resistance mutations (DRM) [73]. Nevertheless, it was the introduction of 
combined antiretroviral therapy (cART) in 1996, which revolutionised the treatment of HIV-
1 [74]. This strategy has brought effective virologic suppression, significant recovery of 
immune function, marked improvement in clinical symptoms, and remarkable extension of 
lifespan with improved quality of life.  
During the last three decades, the US Food and Drug Administration (FDA) approved over 
25 ARVs from six mechanistic classes or subclasses for the treatment of HIV. The six classes 
include: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside 
reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer 
inhibitors (INSTIs), a fusion inhibitor (FI), and an entry inhibitor- a CCR5 antagonist [74]. 
Three or more ARVs from at least two different drug classes are combined in the cART 
regimens. The three main classes recommended for the first-line ART regimen include 
NRTIs, NNRTIs, and PIs [72].  
The cART are effective in dramatically suppressing the virus replication and reducing the 
plasma viral load (VL) to the level below the limit of detection of sensitive assays (50 
copies/ml) [75]. The widespread use of the currently available ARVs has led to a significant 
decline in morbidity and mortality. As a result, AIDS-related deaths declined by over 48% 
from a peak of 1.9 million [1.7 million–2.2 million] in 2005 to 1.0 million [830 000–1 2 
million] in 2016 [76]. The UNAIDS also sets an ambitious strategy called 90-90-90 (where, 
90% of PLHIV knows their HIV status by 2020; 90% of people who know their HIV status 
accessing treatment; and 90% of people on treatment having suppressed viral loads, so they 
remain healthy) with targets to end the AIDS epidemic by 2030 [7]. About 20.9 million 
[18.4 million – 21.7 million] PLHIV were accessing ART in June 2017 [13]. About 11.7 
million PLHIV in eastern and southern Africa were accessing ART with 60% regional 
coverage in 2016. Another 2.1 million PLHIV with about 35% coverage were accessing ART 
in western and central Africa during the same period [13].  
1.5.2 HIV-1 drug resistance (HIVDR) 
HIVDR is caused by mutations in the virus genetic structure that affects the activity of a 
particular single or combined drugs [77]. Emergence  of HIVDR depends on the occurrence 
of genetic variation in the virus population plus the selection of drug resistance variants in the 
process [78]. The HIV-1 genetic variability is due to lack of ability by its RT enzyme to 
proofread and repair nucleotide sequences during the viral replication process [79]. This 
along with the high viral replication rate (at a rate of 10
10
 – 1011 viral particles per day) leads 
to continuous accumulation of a pool of genetically diverse viruses (quasispecies) [80]. The 
expansion of drug resistance variants is influenced by fitness of the virus; how long the 
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replication process has continued while the individual was receiving the ART; and the genetic 
barrier of the ARV agents [78, 81].  
All the currently available ARVs, including newer classes, are at risk of being partially or 
fully inactive as a result of the emergence of HIVDR. Two type of HIVDR: pretreatment 
drug resistance (PDR), and acquired drug resistance (ADR) describe the way an infected 
individual got the drug resistance [82].Transmitted drug resistance (TDR), which is detected 
among treatment naïve individuals without history of ARV exposure, is described within 
PDR.  
1.5.2.1 Pretreatment HIV-1 drug resistance 
PDR is detected in ARV naïve individuals initiating ART for the first time or people with 
prior ARV exposure and initiating or reinitiating first-line ART [77]. It may have been 
transmitted at the time of infection, or it may be acquired as a result of prior ARV drug 
exposure such as in women exposed to ARVs for prevention of MTCT of HIV, in people 
who have received pre-exposure prophylaxis, or in individuals reinitiating first-line ART 
after a period of treatment interruption without documented virologic failure.  
The prevalence and the extent of the problem widely vary with geographical locations and 
drug types. Along with the widespread use of ART and increasing number of people 
accessing the treatment, the prevalence of PDR has substantially increased in low- and 
middle- income countries (LMIC). Since 2001, the prevalence of NNRTI PDR has 
significantly increased globally [77]. Among 11 countries included in the WHO’s survey of 
PDR conducted during 2014 – 2016, seven presented over 10% PDR prevalence in adults 
initiating ART. The WHO HIVDR report also showed PDR prevalence to NNRTIs of greater 
than the 10% threshold in six of the 11 countries. Among the LMICs, more rapid annual 
increments reported from eastern Africa (29%) and southern Africa (23%) compared to 
western and central Africa (17%), Latin America (15%), and Asia (11%). The survey also 
reported a higher PDR prevalence to NNRTIs among PLHIV initiating first-line ART with 
prior ARV exposure (21.6%) as compared to ART naïve (8.3%).  
In addition, a systematic review from sSA showed significantly higher PDR NNRTI 
prevalence among children exposed to ARV drugs for prevention of MTCT (43%) as 
compared to unexposed once (13%) [83]. WHO recently recommended countries to make 
changes in their first-line regimen from NNRTI-based to non-NNRTI-based ART regimens, 
such as INSTIs if the population level of PDR NNRTI reaches the 10% threshold [84]. 
However, the risk of HIVDR associated to the newer class of second-generation INSTIs is 
not clearly known. 
The prevalence of PDR to the three main ARV drug classes was reported increasing in 
resource rich settings (RRS), although it stabilized later as a result of the quality of ART 
services, where genotypic resistance test (GRT) is part of the routine care [85, 86]. Although 
the figures have declined overtime, the prevalence generally varies between 9% – 15% in the 
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US and European countries [86-89]. PLHIV in the RRS also have higher chance of accessing 
newer ARVs from different drug classes. 
1.5.2.2 Acquired HIV Drug Resistance (ADR) 
Despite the remarkable achievements observed over the last decades, emergence of HIVDR 
among individuals accessing ART remains to be an important issue. ADR develops when 
HIV mutations emerge due to viral replication in individuals receiving ARV drugs [84]. 
Suboptimal treatments and non-adherence to treatment are the main factors for emergence 
and accumulation of drug resistance HIV-1 variants. Through onward transmission of the 
ADR, ART naïve individuals could get drug resistance strains with subsequent effects on 
treatment outcome both at individual and population levels [82]. However, as a number of 
factors contribute for the emergence and onward transmission rate of the ADR, the 
prevalence and extent of the problem varies geographically.  
The decline in number of patients exposed for monotherapy; the increasing use of more 
tolerable and potent cART; and routine use of viral load and GRT have largely contributed 
for the reduction of ADR in RRS [86]. For example, a study conducted in Sweden between 
1997 and 2011 reported a rapid decrease in the prevalence of major HIVDR mutations, most 
rapidly between 2003 and 2007 [90].  
In contrary to the RRS, in resource limited settings (RLS) the use of standardized ART 
regimens with limited treatment options; treatment interruptions due to drug stock outs; and 
poor treatment monitoring systems hugely influence the emergence and onward transmission 
of ADR [91, 92]. Reports from sSA cohorts have revealed higher rates of HIVDR among 
treated patients than what was expected [93, 94]. However, unlike in RRS, viral load and 
GRT are not used to monitor and guide the ART service in the RLS, where there could be 
potential misclassification of patients’ treatment outcome [95, 96]. 
For example, a review from RLS on GRT among people who failed therapy after 12 months 
of ART reported a 60% drug resistance rate to any drug class (NRTI 55%, NNRTI 46%), but 
no drug resistance was identified from the remaining 40% treatment failure patients, which 
could be due to very poor adherence or treatment interruptions [97]. In the absence of GRT, 
individuals experiencing treatment failure, but without HIVDR, would have been 
unnecessarily switched to second-line ART regimens.  
In a multicenter cohort study from six sSA countries, 70% of those successfully sequenced 
samples of virologic treatment failures harbored more than one DRM and 49% had dual-class 
(NRTI and NNRTI) resistance, with an average of 2.4 DRMs per sequence (range, 1–8) [98]. 
The most commonly observed DRMs include M184V, K103N, Y181C, and G190A. 
Thymidine analogue mutations (TAMs) reported to contribute to NRTI-associated DRMs in 
substantial proportion of the sequences. The study noted that K65R was frequently selected 
by tenofovir (TDF) (28%) or stavudine (d4T) (15%).  
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Another multicenter study on adult HIV treatment cohorts and clinical trials of HIVDR 
testing in Europe, Latin- and North- America, sSA, and Asia reported a high proportion of 
DRMs among virologic failure patients who were on a TDF-containing first-line regimen 
[92]. The prevalence of TDF-associated DRMs was highest among sSA patients (57%) 
compared to Europe (20%). Those individuals from sSA also had notable DRMs to other 
ARVs in their regimen, which could lead to virtually compromise all combination ART 
regimens in the region. TDF-resistant viruses had been reported to have substantial 
transmission potential. The study also noted that viral strains affected TDF-resistance in 
Europe, although it was not main driver of the resistance among viruses circulating in sSA. 
However, previous studies from Africa reported that HIV-1C rapidly develops K65R-related 
resistance to TDF [99-101].  
1.5.2.3 Resistance to nucleoside analagoue reverse transcriptase inhibitors (NRTIs)  
The first antiviral drug approved for the treatment of HIV was zidovudine (ZDV) from the 
NRTI group. The NRTI drug class has continued to be the core element of the cART [102]. 
The HIV-1 RT enzyme has been used as a major target for anti-HIV drug development such 
as ZDV, emtricitabine (FTC), lamivudine (3TC), TDF, d4T, abacavir (ABC), and didanosine 
(ddI) [72, 103]. NRTIs are prodrugs that require intracellular metabolic conversion into their 
pharmacologically active 5'-triphosphate form before they are incorporated into the proviral 
DNA at the 3'-end. The RT enzyme incorporates phosphorylated NRTIs via competing 
natural deoxynucleoside triphosphates (dNTPs) [104]. Then proviral DNA formation is 
terminated because of lack of a 3'-hydroxyl group or as a result of an altered sugar moiety, 
which prevents incorporation of incoming nucleotides [103-105].  
HIV-1 develops resistance to NRTIs through two main mechanisms including NRTI 
discrimination and NRTI excision [72]. The first mechanism involves discriminatory 
mutations through which the RT enzyme avoids binding of the NRTI and retains its ability of 
recognizing the analogous natural dNTP substrate, which results in diminishing NRTI 
incorporation into the proviral DNA chain, where the virus carries on its proliferation [106]. 
A number of individual or groups of mutations that occur at or near the drug binding sites of 
the HIV-1 RT gene can promote resistance to most NRTIs through selective impairment of 
the enzyme’s ability to incorporate analogues into the proviral DNA [107]. 
Discriminatory mutations including K65R, L74V, Q151M, and M184V/I weaken the 
enzyme’s affinity towards NRTI, but without considerable affinity change towards the 
corresponding natural dNTP. For example, the K65R discriminatory mutation confers 
reduced polymerization rate for incorporation of all NRTIs and viruses with this mutation 
have decreased susceptibility for TDF, 3TC, FTC, ddI, and ABC, but no significant resistance 
for ZDV and d4T [72]. M184 is located at the heart of the catalytic site of the RT enzyme and 
M184V/I interfere with the proper positioning of lamivudine triphosphate within the catalytic 
site. Hence, these mutations confer the virus very high levels of resistance to 3TC and FTC 
[106, 107]. 
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Multiple Q151M complex mutational patterns develop as a result of Q151M with other 
accompanying mutations A62V, V75I, F77L, and F116Y confer the virus high level 
resistance to most NRTIs (ZDV, d4T, ddI and ABC), but minimal susceptibility changes to 
3TC, FTC and TDF. Other mutations at β3–β4 hairpin loop (positions 62 – 72 including 
T69N, K70E/G/Q mutations or T69 deletion) are also associated with the Q151M complex. 
L74V mutation also confers the virus resistance to ABC and ddI and it is associated to lower 
virologic response to TDF-based regimens [72].  
Another major mechanism involves nucleotide excision that selectively removes NRTIs from 
3' end of the chain terminated DNA primer in order to restore the DNA synthesis [106]. 
Removal of the nucleoside analogue from the terminated DNA chain is associated with a 
group of mutations commonly called TAMs [75, 107]. These mutations can promote 
resistance to almost all nucleoside and nucleotide analogues. There are two distinct TAM 
pathways: TAM1 pathway (M41L, L210W, and T215Y) and the TAM2 pathway (D67N, 
K70R, T215F, and K219E/Q) [75]. Once the RT acquires TAMs, further mutations such as 
T69 insertion complex could be developed with potential resistances to different NRTIs [72]. 
1.5.2.4 Resistance to non-nucleoside analagoue reverse transcriptase inhibitors (NNRTIs)  
Unlike NRTIs, NNRTIs do not require intracellular metabolic conversion in order to employ 
their pharmacological activities [72]. An NNRTI binds to a noncatalytic allosteric pocket 
adjacent to the active site of the RT [107]. This noncompetitive binding induces 
conformational changes in the RT structure, which ultimately limit the enzymatic activity of 
RT and blocks the DNA polymerization process. Because of their minimum side effect and 
less toxicity, NNRTIs also play central roles in the treatment of HIV-1. The five approved 
NNRTIs include nevirapine (NVP), delavirdine (DLV), efavirenz (EFV), etravirine (ETR), 
and rilpivirine (RPV) [72]. 
Emergence of DRMs usually at the NNRTI-binding pocket reduces their binding affinity and 
could diminish or completely abolish their therapeutic efficacy. The earlier generation 
NNRTIs (NVP and EFV) have weak genetic barrier to drug resistance and DRMs quickly 
emerge. Only a single mutation at its binding site can induce a high level of resistance [72, 
75]. Whereas, the later generation NNRTIs (such as ETR and RPV) have greater efficacy 
even against the drug resistant viruses and due to their conformational flexibility, they have a 
better genetic barrier towards the emergence of DRMs [72]. However, due to the narrowness 
of the binding site, NNRTI-associated DRMs are highly overlapping [108, 109].  
The primary DRMs conferring resistance to NNRTIs are formed by amino acids with the 
following positions: L100, K101, K103, V106, T107, V108, V179, Y181, Y188, G190, 
F227, W229, L234, and Y318 of p66 and E138 of p51 [72]. K103N, Y181C and G190A are 
the three most common single mutations conferring high level resistance to all NNRTIs of the 
first-generation causing clinical failure [72, 75]. Although NVP resistance is often associated 
with Y181C mutation, it is also associated with Y188C, K103N, G190A, and V106A 
mutations [107, 108]. EFV has some common resistance mutations with other NNRTIs 
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including K103N, Y188L and G190A/S. Initial resistance to EFV is generally characterised 
by the K103N mutation, but Y188L mutation also involves [72, 107, 108, 110].  
ETR and RPV have been developed in such a way that they have highly flexible structure 
with high genetic barrier, which allows them to efficiently bind even in the presence of 
regular NNRTI-associated DRMs [110-112]. Although it has a number of resistance 
associated mutations such as L100I, Y181C/I/V, K101P, and V179F, the K103N is not a 
major issue for ETR [112]. ETR, is therefore, recommended for use in patients who harbor 
the K103N mutant variants [108]. Due to the similar chemical structures, RPV has similar 
resistance mechanisms as ETR [72, 110]. 
1.5.2.5 Resistance to protease inhibitors (PIs) 
The chemical structure of PIs resembles the viral peptides that are normally recognized and 
cleaved by the HIV-1 PR. PIs display a strong affinity for the active site of the PR and when 
they competitively bind to the active site of the enzyme, proteolytic cleavage of the gag and 
gag-pol is inactivated [75]. This in turn prevents the maturation of viral particles to infectious 
viruses. FDA approved nine PIs including atazanavir (ATV), darunavir (DRV), 
fosamprenavir (FPV), indinavir (IDV), lopinavir (LPV), nelfinavir (NFV), saquinavir (SQV), 
tipranavir (TPV), and ritonavir (RTV) for the treatment of HIV-1 [72, 108]. PIs are part of the 
first-line regimens in RRS, but their availability is limited in Africa, and they are reserved for 
second-line therapy [113]. 
HIV develops resistance to PIs by accumulating mutations that leads to reduced binding 
affinity to the drugs while retaining its binding affinity to natural substrates. PI-associated 
DRMs occur with amino acid substitutions within the active site as well as non-active distal 
sites [72, 107]. PI resistance occurs through a stepwise accumulation of mutations, which 
produce conformational changes in the PR binding site followed by secondary compensatory 
mutations that improve the enzymatic activity, and in some cases rescue the viral fitness [75]. 
The PI-associated DRMs include D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, 
V82A/F/T/S/L, I84V, and L90M. Cross-resistance is common among PIs as they share 
relatively similar chemical structures [72]. 
1.5.2.6 Resistance to integrase strand transfer inhibitors (INSTIs) 
The INSTIs interferes with catalytic activity of IN. They bind to the catalytic core domain 
(CCD, amino acids 50 – 212) of the enzyme and target the integration process at the strand 
transfer step [114]. They interact with two essential viral elements including the IN and the 
viral DNA. The three clinically approved INSTIs include raltegravir (RAL), elvitegravir 
(EVG), and dolutegravir (DTG), which bind to the catalytic core of IN [115]. INSTIs 
associated DRMs occur within the IN active site near the amino acid residues that coordinate 
the essential magnesium cofactors [114].  
Resistance to RAL arises from three major independent pathways or sets of mutations as 
defined by primary/signature mutations at positions Y143, Q148, and N155 [75]. These 
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primary/signature mutations generally observed with specific secondary mutations and the 
mutational pathways are believed mutually exclusive, which do not appear in the same viral 
genome [114]. The Q148 mutational pathway includes Q148H/K/R accompanied by other 
subsequent mutations such as L74M, E92Q, T97A, G136R, E138A/K, G140A/S, and V151I. 
The N155H mutational pathway could be associated with L74M, T97A, E157Q, and 
G163K/R. The Y143 pathway consists of Y143C/H/R mutations with L74A/I, T97A, 
G163K/R accessory mutations [72].  
The INSTIs share similar inhibition mechanism; hence cross-resistance becomes a common 
phenomenon among these drugs. For example, the two RAL major resistance mutational 
pathways at Q148 and N155 along with their accessory mutations have also been selected by 
EVG, which shows a similar resistance mutation profile as RAL [115]. Nevertheless, EVG 
does not structurally interact with the IN residue Y143 and the Y143 mutational pathway 
could not confer cross-resistance to this drug. On the other hand, specific mutations that 
confer resistance only to EVG appears at position T66 such as T66I/A/K. E92Q also confers 
high level resistance to EVG as compared to RAL [72]. In contrary, compared to RAL and 
EVG, DTG has lower genetic barrier to drug resistance, although R263K and G118R 
mutations confer certain level of resistance to this drug [115]. 
1.5.2.7 Resistance to entry inhibitors 
HIV entry inhibitors can be classified into three groups: attachment inhibitors, co-receptor 
antagonists, and fusion inhibitors [116]. However, so far FDA approved only two drugs from 
two different classes of entry inhibitors: maraviroc (MVC) as a co-receptor antagonist, and 
enfuvirtide (ENF, T-20)  as a fusion inhibitor [72]. MVC is a selective small molecule CCR5 
antagonist, which  targets the interaction between gp120 and CCR5 and inhibits the virus 
entry through altering the conformation of the receptor [117]. T-20 is a 36 amino acid long 
synthetic peptide fusion inhibitor targeting fusion activity of the HIV-1 gp41 [118].  
One of the resistance mechanisms employed by HIV-1 against MVC is tropism switching 
using CXCR4 co-receptor instead of CCR5 to enter into the cell [119]. However, studies have 
shown multiple mutations that occurred in V3 loop region of the env region allows the virus 
to use the MVC occupied CCR5 co-receptor as well [72]. Additional resistance mechanisms 
employed by the virus include increased affinity for the co-receptor, utilization of inhibitor-
bound receptor for entry, and faster rate of entry [75]. In view of the fact that selection of 
CXCR4 tropic virus (which could lead to faster disease progression) due to CCR5 antagonist 
treatment; tropism switching has been a concern in the therapeutic administration of MVC 
[75, 108]. Resistance mutations to T-20 emerge through a stretch of amino acids, which is 
located at position 36 – 45 of gp41 [118].   
1.6 MONITORING STRATEGIES 
In sSA countries, when to start and monitor ART has been mainly based on a public health 
approach adapted from WHO. Clinical decision making and when available CD4 cell count, 
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rather than viral load testing, has been the main monitoring strategies in the region [113, 120]. 
However, the monitoring strategies have been continuously evolved [121]. 
1.6.1 When to start ART 
The WHO recommendation about when to start ART has been continuously updated over 
time. For example, till 2013 in most RLS including Ethiopia, the decision to start ART was 
based on clinical and immunological criteria adapted from the WHO’s 2006 guideline. In this 
guideline, the optimum time to commence ART was set to be before patients become unwell 
(present with their first OI). The guideline recommended not to initiate ART before patients’ 
CD4 cell count drops below 350 copies/μl [5, 120]. Then, the 2013 WHO consolidated 
guideline recommended initiating ART for all HIV infected adults with a CD4 cell count at 
or below 500 cells/μl regardless of their WHO clinical stage, giving priority to those with 
severe or advanced diseases (WHO stage III or IV) or a CD4 count at or below 350 cells/μl 
[113]. Recently, a test and treat strategy has been recommended with final targets of universal 
treatment access [121, 122]. This recommendation has allowed the treatment of all PLHIV 
irrespective of their CD4 cell count [121]. 
Reports have revealed that immediate initiation of ART has impact in reducing both AIDS-
related and serious non-AIDS-related events, as well as reduction in transmission of HIV 
[121]. However, there are challenges in retaining PLHIV in care particularly in LMIC, where, 
multiple factors related to the health care delivery systems could facilitate or hinder retention 
of patients [123]. There are also uncertainties in relation to the accelerated ART initiation, 
which may lead PLHIV to start the treatment before they are well prepared, with adverse 
consequences for adherence and treatment outcomes. Hence, starting the ART based on a 
person’s informed decision including provision of information about the benefits of early 
treatment, but also the required lifelong commitment; the risk of delaying the treatment; and 
availabilities of adherence supports are recommended [121]. Once a patient has started the 
treatment, uninterrupted supply of ART with continuous monitoring are essential for 
sustainable viral suppression and optimal treatment outcome [123].  
1.6.2 Monitoring response to ART and diagnosis of treatment failure 
The currently available ART is not curative, but suppresses the virus replication. The 
treatment reduces the plasma viral load below the detection limit of sensitive assays (<50 
copies/ml), preventing further loss of CD4
+
 T-lymphocytes and deterring progression to 
AIDS [75]. This allows PLHIV accessing cART to have near-normal life expectancy and to 
decrease further transmission of HIV [124]. Hence, viral load (HIV-1 RNA level) and CD4 
count are the two surrogate markers of ART outcomes and disease progressions, which have 
been used to manage and monitor the HIV-1 infection for decades [125].  
Viral load is generally accepted as the gold standard for monitoring the ART response and is 
a marker of the treatment outcome [125] . It is the most important indicator of initial and 
sustained treatment response, which is recommended as the preferred monitoring approach to 
diagnose and confirm ART failure, but its use has mostly been limited in RRS. Although the 
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optimal threshold for defining virologic failure and for switching ART regimens has not been 
established, WHO recommended a threshold of 1000 copies/ml [121]. This recommendation 
in view of the fact that the risk of transmission of HIV to other individuals as well as the 
progression of an infection to AIDS is minimal when the HIV-1 RNA level is below 1000 
copies/ml [126]. Below 1000 copies/ml, viral blips or intermittent low level viremia (50 – 
1000 copies/ml) can occur during effective treatment, but have not been associated with an 
increased risk of treatment failure [127]. Most standard viral load platforms using plasma 
specimens have good diagnostic accuracy at this threshold level [121].  
Compared to CD4 cell count, monitoring with viral load has been found to associate with 
satisfactory outcomes in early detecting treatment failure [128]. However, considering the 
large number of people accessing ART coupled with the deficiencies in the health care 
system in LMIC including sSA countries, viral load monitoring has not been the standard of 
care in such regions. Hence, when viral load is not routinely available, CD4 count and 
clinical monitoring are recommended to be used for the diagnosis of treatment failure. 
However, immunological and clinical criteria have poor sensitivity and specificity to detect 
treatment failure, particularly at higher CD4 cell counts, and more accurate immunological 
criteria are yet to be identified [121, 129].  
1.6.3 Treatment outcome measurements  
Once ART is initiated, the outcome can be measured in three ways: clinically, by disease 
progression and WHO clinical staging; immunologically, by measuring the temporal trends in 
CD4 cell counts; and virologically, by measuring the plasma HIV-1 RNA load [121]. 
Accordingly, treatment failure is defined clinically, virologically and immunologically, but 
slightly different definitions are used in children, and adult and adolescent populations. In 
adults and adolescents, the following definitions are given by WHO:-  
Clinical failure: new or recurrent clinical event indicating severe immunodeficiency such as 
WHO stage IV diseases and certain WHO stage III conditions including pulmonary TB and 
severe bacterial infections after 6 months of effective treatment.   
Immunological failure: CD4 cell count at or below 250 cells/µl following clinical failure; or 
persistent CD4 levels below100 cells/µl.  
Virologic failure: a persistently detectable viral load exceeding 1000 copies/ml (that is, two 
consecutive viral load measurements within a 3 month interval with adherence support 
between measurements) after at least 6 months of starting a new ART regimen. 
Retention in care and adherence to medication are the other most key indicators in monitoring 
the treatment outcome among patients accessing ART. For PLHIV who are accessing 
treatment, uninterrupted ART and continual monitoring are essential for sustained viral 
suppression and optimal treatment outcomes. Hence, treatment outcome is usually analysed in 
two ways: on-treatment (OT) analysis and intention-to-treat (ITT) analysis. 
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On-treatment (OT) analysis: accounts only for patients who continue the treatment 
(compliant patients). This type of analysis includes the number of patients with virological 
suppression or virological failures. However, OT analysis loses the benefits of initial 
randomization because it accounts only patients who continue the ART. In addition, because 
it is unlikely that compliance varies randomly among the comparison groups, bias is probable 
[130]. 
Intention-to-treat (ITT) analysis: compares patients in their randomly assigned treatment 
groups. ITT includes every subject who is randomized according to randomized treatment 
assignment. It ignores noncompliance, protocol deviations, withdrawal, and anything that 
happens after randomization. Hence, in addition to virologic failure, ITT analysis includes 
patients who have died or who were LTFU, and/or who stopped ART for different reason. 
However, a better application of the ITT approach is possible if complete outcome data are 
available for all randomized subjects [131]. 
1.7 GENOTYPIC ASSAYS FOR HIV-1 DRUG RESISTANCE  
Genotypic assays are used to determine the presence of mutations that are known to confer 
decreased drug susceptibility to an organism [132]. The genotypic assays are based on 
analysis of the nucleotide sequence generated from genomic regions conferring phenotypic 
resistance to the organism. For various reasons, the genotypic assays have been commonly 
used for HIVDR testing [132, 133]. DRMs are identified through assessment of specific gene 
sequences in comparison to a reference (wild-type) virus, though the most commonly used 
reference sequence is the subtype B consensus sequence [78]. A number of genotypic 
approaches are available for detection of DRMs including population-based sequencing, 
whole-genome sequencing, allele-specific, and next-generation sequencing (NGS) [133-135].  
1.7.1 Population-based sequencing 
Population-based Sanger sequencing (PBSS), which is based on direct polymerase chain 
reaction (PCR) dideoxynucleotide sequencing, is the most conventional GRT method [136]. 
It has been used for HIVDR testing to guide ART and monitor DRMs at least in RRS [137, 
138]. GRT can be done using either commercially available genotypic assays (ViroSeq and 
TruGene) [136] or in-house methods [139, 140]. However, unlike in-house methods, the 
commercial assays are more expensive and may not provide flexibilities [140]. These direct 
sequencing assays have been widely used for HIVDR testing in clinical settings as well as 
surveillance purposes [137, 141].  
Although PBSS can provide detailed sequence information and detect all possible DRMs, the 
assay is not sensitive enough to detect low-level drug resistant variants that are present at 
levels below 20% of the circulating viral population [133]. Hence, more sensitive assays with 
features overcoming various limitations of the traditional PBSS have been developed for 
genotyping HIV including allele-specific PCR (AS-PCR) [134, 142, 143], and NGS [133, 
144].  
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1.7.2 Allele-specific PCR (AS-PCR) 
The drug resistant variants that are not detected by conventional assays have been shown to 
have influence on HIV treatment response. This calls for application of mutation-specific 
assays (such as AS-PCR) in defining the impact of drug resistant minority variants on 
therapeutic outcome [134]. Compared to the conventional PBSS method, minority-specific 
assays have high sensitivity and better capacity to detect low frequency mutations down to 
0.01% [142, 145]. Currently, there are several allele-specific assays allowing specific 
investigation of DRMs with a higher analytical sensitivity for minority HIV variants [134, 
143, 145-147].  
Even if AS-PCR is currently one of the most sensitive assays being used in studying minority 
DRMs, it has limitations that it can only analyse one or a few mutations at a time [134]. 
Considering the fact that allele-specific assays are specific to mutations, their benefits depend 
on the mutation being studied. In view of such limitations, multiplex allele-specific assays 
that can simultaneously detect major HIVDR mutations at several loci have been developed 
[148, 149].  
1.7.3 Next-generation sequencing (NGS)  
The field of genomics is being transformed because of the recently evolved new deep 
sequencing techniques including NGS, which is also known as “second-generation”, 
“massive parallel” or “deep” sequencing [144, 150]. Several new high-throughput DNA 
sequencing instruments are made available with their own intrinsic performance metrics such 
as the number of reads obtained; the read lengths; the reading accuracies; the time needed to 
run the assay; and cost of the assay [133]. These technologies generate an enormous amount 
of information at relatively low cost in a short period of time than the conventional PBSS 
[96]. The technologies are continually evolving, opening new and more affordable 
opportunities for their implement in clinical laboratories [151, 152]. 
The use of deep sequencing technologies to evaluate the impact of minority variants and rare 
non-CCR5 variants promotes the assays to be important in the field of HIVDR [135, 144, 
150]. For example, new assays to determine the specific tropism of viruses are essential for 
successful treatment with ARV classes targeting CCR5 or CXCR4 [144]. Hence, NGS assays 
with such increased sensitivity play an important role in HIVDR surveillance, to study 
transmission of drug resistant viruses, to determine the impact of drug resistant minority 
variants on therapeutic outcomes [133].  
The commonly used NGS technologies include pyrosequencing by 454 Life Sciences/Roche 
(454/Roche); reversible terminator sequencing-by-synthesis (SBS) by Illumina; and single-
molecule sequencing by Pacific Biosciences (PacBio) [153]. They differ in sequencing 
chemistry, speed, throughput, read length, error rates and error patterns. Each of the three 
technologies can be used to analyse viral genomes, but none enables sequencing regions 
larger than a few hundred bases with sufficiently high accuracy [154].  
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1.7.4 Whole-genome sequencing 
Most of the currently available genotypic assays used in the clinic could provide information 
on DRMs, which is restricted to full-length PR and partial RT regions. As mentioned above, 
the currently available NGS technologies provide sequence reads of only a few hundred bases 
with sufficiently high accuracy, and subsequently virus diversity is typically assessed only by 
studying single nucleotide positions or mutations within a read length [155]. This led for the 
development of a growing number of in-house methods to address the need for simultaneous 
HIVDR testing against all ARV classes [135, 156].  
Whole HIV-1 genome analysis also provides information about molecular epidemiology, 
population structures, and pathogenesis of the infection. This method could also contribute in 
the development of new effective preventive and treatment strategies including vaccine 
design [155]. In addition, the full genomes are also of interest for detection of quasispecies 
and tracking immune evasion through variation in CD8
+
 T-lymphocyte epitopes with linkage 
elsewhere in the genome [154]. 
So far, genome-wide reconstructions were only achieved with simulated data in silico; thus, 
experimental amplifications and sequencing strategies, combined with appropriate 
bioinformatics methods for haplotype inference, are needed to phase multiple overlapping 
sequence reads, and to allow reconstruction of whole genomes. Due to its small genome, high 
intra-patient genetic diversity and clinical relevance, HIV-1 is an attractive model system for 
developing such a global haplotype inference methodology [154].  
1.7.5 Bioinformatic tools 
Because of the large number of mutations and mutational patterns that confer drug resistance 
it may be difficult to interpret results genarted from genotypic assays. To facilitate the use of 
the large amount of data generated from genotypic assays a range of bioinformatics tools and 
databases have been developed [157]. The bioinformatics tools and databases have been 
applied for predicting HIV subtypes, co-receptor tropism, response to combination of 
therapy, and drug resistance. These kinds of applications of the bioinformatics tools support 
clinical decision making based on the viral genomic data. With a number of available 
softwares, the development of computational methods that correlates specific genotypes with 
resistant phenotypes can allow effective therapy design against drug resistant HIV variants 
[157, 158]. Bioinformatic tools are also used in order to understand the mechanism of drug 
resistance development and to model evolution of the sequences under the selective pressure 
of combination therapies as well. 
Generally, the methods used for the prediction of phenotypic drug resistance from genotypes 
can be subdivided into three groups including knowledge based, data based, and physics 
based approaches. The knowledge based approaches rely on extracting information on drug 
resistance from several sources, mostly from published literatures. Data based methods rely 
on applying machine learning techniques to matched genotype – phenotype pairs. Physics 
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based methods combine phenotypic drug resistance factors with computed inhibitor binding 
affinities, taking into account mutations in the genotype [159]. 
However, most of the genotype interpretation algorithms are knowledge based approaches, 
and clinical evaluation of the interpretations is not always straightforward. These 
interpretation algorithms apply a set of rules or scores for each mutation and drug. Hence, 
accurate predictions can be valuable for prescribing the most effective ARVs for infections 
with resistant HIV [160].  
The commonly used interpretation algorithms include: Stanford HIVdb (https://hivdb. 
stanford.edu/), ANRS algorithm (http://www.hivfrenchresistance.org/), Geno2Pheno 
(https://www.geno2pheno.org/), HIV-grade (https://www.hiv-grade.de/cms/grade/ 
homepage/), and REGA (http://www.bioafrica.net/HIVdrugresistancetools.html ) [161]. 
There are also HIVDR databases, which are essential to store, represent, and analyse the data 
on drug resistance and to retrive these data when needed. The three common HIVDR 
databases include: EuResist database, Stanford database, and Los Alamos HIV Sequence 
Database. The Stanford database allows users to screen their own DNA sequences for 
resistance conferring mutations. The Los Alamos HIV Sequence Database 
(https://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html) makes an easy access to all 
published genomic DNA, coding protein sequences of HIV with subtype and sequence 
annotations. The database also offers several tools and programs for analysis [162].  
In addition to the prediction of HIVDR, bioinformatics tools have also been developed for 
prediction of the virus co-receptor tropism based on interpretation of V3 sequences of the env 
region [163]. The first genotypic algorithm designed to predict HIV-1 tropism took into 
account only the charge of amino acids at two key residues located within the V3 loop (amino 
acids 11 and 25). Although estimates using the “11/25 charge rule” are fairly satisfactory 
[67], other positions within the V3 region are also currently known to influence viral tropism 
as well, causing occasional disagreements. Hence, currently genotypic bioinformatics tools 
consider the entire V3 sequence [163]. In addition to the “11/25 charge rule”, bioinformatics 
based algorithms including position specific scoring matrix (PSSM), Geno2Pheno, and 
PhenoSeq are used to predict the HIV-1 co-receptor tropism [164]. 
1.8 ANTIRETROVIRAL TREATMENT IN ETHIOPIA 
In Ethiopia, the ART programme was officially started in 2003 as fee-based system [165] and 
free ART was launched in 2005 with support from the government, the U.S. President’s 
Emergency Program for AIDS Relief (PEPFAR), and the Global Fund to Fight AIDS, 
Tuberculosis and Malaria [166]. Subsequently, the service has been decentralised and made 
available at increasingly large numbers of both health centers and hospitals throughout the 
country using the WHO public health approach. Integration of the service at lower-level 
health facilities and task shifting to low- and mid- level health workers have greatly enabled 
scaling up of ART in Ethiopia [167, 168]. By the end of 2016, over 420 000 PLHIV were 
accessing the treatment with an approximately 60% national coverage [35, 76]. Although a 
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high rate of ART coverage has been achieved in adults, the coverage remains low among 
children. Reports also revealed that a significant number of patients enrolled into the ART 
were dropped out from the service [6, 44].  
In Ethiopia, the eligibility criteria for initiation of ART have been improved over time. For 
example, until 2012, the criterium for initiating ART was set at CD4 count at or below 200 
cells/µl, or WHO stage IV; thenafter, it was improved to less than 350 cells/µl, or advanced 
diseases (WHO stage III or IV). Again in 2014, adaptation of the 2013 WHO consolidated 
guidelines improved the eligibility criteria to CD4 count at or below 500 cells/μl, regardless 
of WHO stages [113, 123]. According to the new national guidelines, initiation of ART is 
based on the recent test and treat eligibility criteria, i.e. ART should be initiated to all PLHIV, 
regardless of their WHO stage or CD4 cell count [35]. 
1.8.1 Antiretroviral regimens in Ethiopia 
The first-line ART regimen in Ethiopia includes a triple therapy: two NRTIs and an NNRTI, 
reserving PIs for second-line, which is the center piece of the public health approach [35]. In 
order to reduce the pill burden and simplify the regimens the use fixed-dose combinations 
(FDCs) is recommended in the guidelines. Hence, a once-daily regimens comprising NRTI 
backbone (TDF + 3TC) and one NNRTI (EFV) is maintained as the preferred choice in 
adults, adolescents and children older than ten years. For children younger than three years a 
PI-based regimen is the preferred approach.  
Thus, the new guideline recommend a once-daily FDC containing TDF + 3TC + EFV as 
prefered first-line regimen, whereas AZT + 3TC + EFV, AZT + 3TC + NVP, and TDF + 
3TC + NVP as alternative regimens [35]. With the previous guidelines both NNRTIs were 
given equal preference [5], but the recent WHO guidelines recommended EFV as the 
preferred option [113, 121]. Regimens containing ABC, d4T and boosted PIs are 
recommended under special circumstances. Recently the use of the second-generation INSTI, 
DTG combined with two NRTIs is recommended as an alternative first line in RLS [121], but 
in Ethiopia it is recommended as a third-line regimen [35].   
Second-line regimens containing a boosted PI plus two NRTIs are recommended as preferred 
strategy for adults, adolescents and also for children when NNRTI-containing regimens were 
used in first-line ART. In general, selection of a second-line regimen depends on the first-line 
regimen that the patient has been taking [35].  
1.8.2 Monitoring strategies in Ethiopia 
Ethiopia has been adapting and implementing series of WHO guidelines for monitoring of the 
ART outcome. For example, the first guideline on the use of ARV was issued in 2003 [165], 
which was later revised in 2005 and 2008 to facilitate a rapid scale-up of ART as per the 
WHO public health approach [5]. In 2014, the country adapted and implemented the 2013 
WHO consolidated guideline of ART for treatment and prevention of HIV [113, 123], and 
recently adapted the 2016 WHO guidelines [121] in its new national guidelines [35]. 
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Monitoring and evaluation tools are also routinely used to track key program performance 
and outcome indicators, which provided limited and primarily aggregated information about 
the effectiveness of ART [5, 35]. 
Clinical parameters and CD4 cell count have been used as the main criteria for monitoring of 
ART. As per the old guidelines, the criteria used to monitor treatment failure include: WHO 
stage IV disease; fall of CD4 cell count to pre-therapy baseline (or below); 50% fall in CD4 
cell count from the on treatment peak value (if known); or persistent CD4 count below100 
cells/µl [5, 120]. However, the performance of clinico-immunological criteria has been found 
to have poor sensitivity, specificity and reliability, which could result in inappropriate 
switching to second-line therapy and consequently it might lead to an increased number of 
resistance mutations [169, 170].  
Although CD4 cell count measurement has been recommended every 6 months or as deemed 
necessary, because of limited availability of the facilities only at certain ART centres, the test 
has been performed through sample referral networking system [123]. The CD4 cell 
measurement facilities have not yet been completely available in every center throughout 
Ethiopia because of the high cost of the instrument and partly because of the large number of 
people accessing the treatment as well. Due to limited laboratory facilities, shortage of 
supplies and trained personnel, the clinical criteria have been used in a substantial proportion 
of patients for monitoring of the ART outcome in the country.  
However, the new national guideline does not recommend CD4 cell count for monitoring 
purpose, rather viral load determination. CD4 cell count is recommended for patients on ART 
only when indicated. HIV-1 viral load measurement is recommended at 6- and 12- months 
after initiation of ART and every 12 months thereafter [35]. Aside from the routinely 
scheduled measurements, viral load test is also recommended whenever there is clinical or 
immunological indication of treatment failure. 
1.8.3 Antiretroviral treatment outcome in Ethiopia 
Despite the observed successes in scaling up of ART throughout Ethiopia, there are only few 
studies showing the treatment outcome in the country. The few available studies reported a 
high rate of early death and LTFU [44, 166]. Because of the fact that until recently viral load 
test had not been used in monitoring of ART outcome in Ethiopia, virologic treatment 
outcomes were reported only by very few sdudies conducted mainly for the purpose of drug 
resistance study. For example, a study from Jimma reported a virologic failure rate of 5.3% at 
month 6 after initiation of ART [171]. Whereas, a study from Gondar showed a virologic 
failure rate of up to 30% at a median time of 24 months of ART [172].  
There are also other few studies with reports of LTFU and mortality after initation of first-
line ART. A retrospective longitudinal analysis study on adults enrolled at 56 health facilities 
from 2006 – 2011 reported a total attration (LTFU and death) rate of 30% at month 36, most 
occurred in the first 6 months [173]. Another earlier retrospective longitudinal analysis study 
conducted at 55 health facilities reported that 9% and 12% patients were transferred out to 
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other facilities, 0.58% and 2.1% switched to second-line ART, 6% and 8% died, and 20% 
and 24% LTFU after 12 and 24 months of ART, respectively [174]. This study also stated 
that decentralisation of the ART service more to primary health facility levels than at 
centralised hospitals could improve retention in care in Ethiopia. 
1.8.4 HIV-1 drug resistance in Ethiopia  
In Ethiopia, there are only a few studies from limited geographical regions mainly from the 
capital city Addis Ababa and Northwest part of Ethiopia, where the prevalence of TDR have 
been reported [175-177]. These studies showed very low rate of TDR among treatment naïve 
individuals. However, so far no surveillance study has reported the extent of TDR at a 
national level. The reported prevalence among ART naïve individuals who were attending a 
public antenatal clinic in Addis Ababa was below 5% [175]. Another study conducted on 
samples from Addis Ababa using AS-PCR reported a 6.5% (6/92) TRD prevalence [134].  
A study conducted among ART naïve HIV-1 infected patients who were seeking treatment at 
Gondar University Hospital, Northwest Ethiopia showed a 3.3% TDR prevalence [176]. In 
another study from the same geographic region reported a 5.6% TDR prevalence according to 
the Stanford University HIVDB drug resistance interpretation algorithms, but 13.1% as per 
the International Antiviral Society–USA (IAS) mutation lists [177]. However, a study from 
Jimma Hospital, Southern Ethiopia reported that half (6/12) of the baseline samples harbored 
resistance to NNRTIs, but all the 12 patients had virologic failure status at month 6 [171].   
Again there are only a few studies with reports of ADR in Ethiopia. A study from Jimma 
Hospital reported an ADR rate of 81.8% (9/11) after 6 months of ART [171]. Two other 
studies from Gondar also reported ADR rates of 75% (6/8) at a median time of 30 months on 
ART [178] and 66% (15/21) after 8 years of treatment [172].  
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2 RATIONALE OF THE THESIS  
Ethiopia remains one of the most heavily affected countries by the HIV-1 epidemic with 
about 740 000 PLHIV [35]. The treatment of HIV-1 has been scaled up for more than a 
decade using the WHO public health approach and a large number of PLHIV in the country 
have been receiving ART with an estimated coverage of 60% by the end of 2016 [35, 76]. Of 
course, the public health approach helped to decentralise and integrate the ART service to the 
low level health care system and indeed have made the treatment more accessible to the 
people in need. However, until recently viral load and GRT have not been part of the current 
standard monitoring strategies like in most other sSA. 
The treatment outcome and the levels of HIV-1 drug resistance had been poorly described 
and reports are available only from a few geographic regions of the country involving a 
limited number of patients. Hence, data has been lacking at the national level. In addition, 
some fragmented reports also showed that a substantial proportion of patients on treatment 
were LTFU [44, 166, 173]. Yet, the factors for poor treatment outcome and discontinuation 
of ART by a substantial proportion of patients are poorly understood. Although the HIV-1C 
was first described in Ethiopia, the status of the epidemic has not been characterised with data 
and samples representative of the country, and hence description of the HIV epidemic 
remains to be determined at the national level.  
Bearing in mind the use of ART for over a decade in Ethiopia with high rate of dropouts, but 
without a comprehensive data about the ART effectiveness and drug resistance at the national 
level, it has been essential to assess the treatment outcome and determine the level and 
patterns of HIVDR across the country. Identifying the baseline predictors of treatment failure 
and LTFU has also been shown to be an important issue that should be addressed in order to 
get information about the factors behind the poor treatment outcome. Therefore, the aims of 
my thesis were to assess the treatment outcome and to determine the level and patterns of 
HIVDR both among treatment naïve patients and virologic failures in Ethiopia. In addition, 
the thesis also aimed at identifying baseline predictors of treatment failure and LTFU. 
Further, molecular characterisation of the epidemic and co-receptor tropism of HIV-1C was 
also the aim of this thesis. To achieve these aims and bridge the prevailing information gaps, 
data and plasma samples were collected from a countrywide HIV-1 cohort, where patients 
from seven university affiliated hospitals in Ethiopia were enrolled. 
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3 OBJECTIVES OF THE THESIS 
3.1 GENERAL OBJECTIVES 
The main objectives of this thesis were to assess the outcome of antiretroviral therapy and to 
investigate the molecular epidemiology of HIV-1C drug resistance using a large countrywide 
HIV-1 cohort in Ethiopia. 
3.2 SPECIFIC OBJECTIVES 
Overall, the objectives were addressed through the following five specific objectives: 
1) To identify baseline predictors of therapy outcome and lost to follow up after 6 and 12 
months of first-line antiretroviral regimen (Paper I). 
2) To assess the presence of surveillance drug resistance mutations and investigate minority 
mutations by population-based Sanger sequencing as compared to next-generation 
sequencing (Paper II). 
3) To evaluate the short-term impact of baseline drug resistance mutations on antiretroviral 
therapy outcome (Paper II) 
4) To describe the HIV-1C molecular epidemiology and tropism trend over the last two 
decades in Ethiopia and to assess the impact on antiretroviral therapy outcome (Paper III). 
5) To investigate the level and patterns of acquired drug resistance mutations in HIV-1C pol 
gene and perform a viral genome wide association study in virologic failure patients (Paper 
IV) 
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4 MATERIALS AND METHODS 
4.1 STUDY DESIGN AND PATIENT POPULATION 
The studies were conducted on data and plasma specimens collected through the Advanced 
Clinical Monitoring of Antiretroviral Therapy in Ethiopia (ACM) cohort.  
In this prospective multi-site adult and adolescent repository cohort of HIV-1 infected 
patients, 874 ART naïve study subjects (age ≥14, both sexes) were enrolled at seven 
university hospitals between October 2009 and December 2011. During the recruitment 
period, 112 to 134 participants were enrolled in each hospital ART clinic. Then, all patients 
started ART as per the national guidelines [5], and were followed up until 2013.  
4.1.1 Establishment of the countrywide national HIV cohort 
The ACM cohort was established through a partnership between ten local and two 
international institutions (Figure 2). The local participating institutions include: HAPCO 
(Federal HIV/AIDS Prevention and Control Office of Ethiopia), EHNRI (Ethiopian Health 
and Nutrition Research Institute, now EPHI- Ethiopian Public Health Institute), ESTA 
(Ethiopian Science and Technology Agency, now MOST- Ministry of Science and 
Technology), and seven university affiliated hospitals. The two international institutions were 
Centers for Disease Control and Prevention (CDC), and Johns Hopkins University (JHU).  
 
Figure 2. Advanced Clinical Monitoring of Antiretroviral Therapy in Ethiopia (ACM) project 
organizational structure. The map shows the geographical locations of the study sites 
(hospitals); : participating hospitals. 
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The ACM was one of the largest HIV cohorts in African settings with over 4000 patients who 
were enrolled from a well-defined study population at seven geographically distinct hospitals 
in Ethiopia. This cohort was also the first and largest clinical study on HIV infected patients 
aimed at assessing the longitudinal effectiveness of ART in Ethiopia. Clinical data were 
obtained from over 4000 patients and clinical and plasma samples from over 1000 patients 
including children.  
4.1.2 Study sites in brief 
The seven study sites include: TASH, Armed Force General Hospital, Gondar Referral and 
Teaching Hospital, Jimma University Specialised Hospital, Mekelle General Hospital, Hiwot 
Fana Referral Hospital, and Hawassa University Referral Hospital. The number of study 
participants enrolled at the respective sites were 119, 122, 134, 112, 126, 128, and 133. All of 
these hospitals are referral hospitals providing service to millions of individuals each. 
Geographically the study sites are well distributed throughout Ethiopia (a map showing the 
locations of the study sites depicted on Figure 3 in Paper II). Briefly, TASH is located in the 
capital city Addis Ababa, central Ethiopia; Gondar Hospital located in the northwest; Jimma 
in the west; Mekelle in the north; Harrar in the east; and Hawassa in the south parts of the 
country. In addition, Armed Force General Hospital is located in Addis Ababa providing 
service to mobile military staff and to their families.  
4.2 DATA AND SPECIMEN COLLECTION AND STORAGE 
Longitudinal data and plasma specimens were collected from each participant. Ten ml whole 
blood was collected at ART initiation and every 6 months thereafter and labeled with specific 
code and date of specimen collection. The blood specimens were then processed at the 
respective hospital laboratories and plasma specimens were transported to EHNRI (located in 
Addis Ababa), and centrally stored at -80°C after registered in a predesigned electronic 
repository database.  
Quantification of HIV-1 RNA viral load was performed centrally at EHNRI using 
NucliSENS easyQ® HIV-1 Nucleic Acid Sequence-Based-Amplification (NASBA) assay 
(BioMérieux Diagnostics) with a lower detection limit of 150 HIV-1 RNA copies/ml. Viral 
load results for each participant at baseline, 6 and 12 months of ART initiation were stored in 
an ACM central electronic database at EHNRI. Other than VL, clinical and laboratory tests 
were performed at the respective hospitals as per the national guideline [5] and stored in the 
central electronic database after quality control checks.  
For the purpose of this study, clinical and laboratory data at ART initiation and follow up 
time points (at month 6 and 12 after initiation of ART) were extracted from the central 
electronic database using a predesigned form. Patient data analysed in this thesis include: 
socio-demographic data (study site, gender, age, educational status, employment status, 
marital status, and spouse HIV sero-status); clinical data (WHO clinical stage, functional 
status, TB, OIs other than TB, BMI – body mass index, and adherence level); treatment 
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history (initial ART regimen, months on ART, history of treatment switch); and laboratory 
data (CD4 cell count, CD4/CD8 ratio, and VL). 
In addition, 1 ml volume plasma (mostly in two 0.5 ml aliquots) of each study participant at 
each available visit (at ART initiation, month 6 and 12) was transported on dry ice from 
EHNRI, Ethiopia to Karolinska Institutet, Campus Flemingsberg, Sweden following the 
standard biosafety levels. At arrival all samples were checked for integrity, registered and 
immediately stored in −80 °C freezer.  
4.3 TREATMENT OUTCOME MEASURES 
The ART outcome was analysed using the two treatment analysis outcome measurements: 
on-treatment (OT) and intention-to-treat (ITT) analyses.  
4.3.1 On-treatment (OT) analysis 
In the OT analysis, only those patients who had VL at the follow up time points were 
included. Virologic treatment failure was defined using two threshold VL values: 150 
copies/ml (the limit of detection of our assay) and 1000 copies/ml (as per the WHO virologic 
failure definition) [179] 
4.3.2 Intention-to-treat (ITT) analysis 
In the ITT analysis, treatment failure was defined as virologic failure as defined above (OT 
analysis), death or LTFU. In this analysis if a patient had no data at the follow up time points 
he or she was considered as LTFU.  
4.4 GENOTYPIC HIV DRUG RESISTANCE TESTS 
Genotypic resistance test was performed on plasma specimens using the following steps: 
nucleic acid extraction; cDNA synthesis; nested-PCR amplification of DNA; DNA 
purification; and population-based DNA sequencing. 
4.4.1 RNA extraction 
For studies included in Paper II – Paper IV, HIV-1 RNA was extracted using the QIAamp® 
viral RNA extraction mini-kit (Qiagen, Hilden, Germany) from 140 μl plasma specimen (if 
VL 10 000 copies/µl) as per the manufacturer’s instruction. However, when the viral load 
was below 10 000 copies/ml, the RNA extraction was done from a 1 ml plasma sample 
through a high-speed centrifugation at 20 000 × g for 60 min in a refrigerated centrifuge at 
4°C condition. Then, using a fine-tip pipet about 860 μl of the supernatant has been carefully 
removed leaving about 140 μl of plasma pellet. Quantity and purity of the extracted RNA was 
checked using NanoDrop (Thermo Scientific, DE, USA) and stored at stored at −80 °C until 
further use.  
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4.4.2 RT-PCR  
For the purpose of Paper II, Paper III, and partly of Paper IV (PBSS assay) complementary 
DNA (cDNA) synthesis was performed by reverse transcriptase polymerase chain reaction 
(RT- PCR) using RevertAid H-minus reagents (Life technologies, Paisley, UK) following the 
manufacturer’s instructions. For second part of Paper IV (NFLG assay), two strands of 
cDNA were synthesised including fragment-1 (Gag-Vpu, F1Gag-Vpu); and fragment-2 (Tat-3 
LTR, F2Tat-3LTR) as described in Grossmann et al. [156]. 
4.4.3 Nested-PCR 
PCR runs were performed with high fidelity KAPA HiFi HotStart ReadyMix (2×) (KAPA 
Biosystem, MA, USA) following the manufacturer’s instructions. In relation to Paper II and 
partly of Paper IV (for the PBSS assay), nested-PCR was performed through a first-round 
PCR using JA203F-C (forward primer) and JA206R-C (reverse) primer pairs, followed by a 
second-round PCR, which was performed using JA204F-C (forward) and JA205R-C 
(reverse) primer pairs as described in Lindström and Albert “in-house” method [139]; and a 
product spanning PR and the first two-thirds of RT gene of the HIV-1 pol-gene (ref HXB2 
position: 2135–3338) was amplified. In Paper III, the env gene encoding the V3-V4 region 
was amplified as described [180], using modified primers: ED5-1F and ED12-1R for the 
first-round PCR run; and ES7-2F and ES8-2R for the second-round PCR. 
For the second part of Paper IV (the NFLG assay), an 8.8 kb genome was amplified into two 
fragments (fragment-1 and fragment-2) by nested- and semi-nested- PCR with seven primers 
as described in Grossmann et al. [156]. Briefly, the 5.5 kb fragment-1 (F1Gag-Vpu) was 
amplified through a first round PCR, which was performed with 0682F and 6352R primers 
followed by a second round PCR run with 0776F and 6231R primers. The 3.7 kb fragment-2 
(F2Tat-3LTR) was amplified in a semi-nested-PCR using a first- and a second-round forward 
primers 5550F and 5831F, respectively and a common reverse primer 9555R. Details of the 
primers used in Papers II – Paper IV are given in Table 1. 
4.4.4 DNA purification  
A 5 μl nested-PCR product was analysed using a 5% ethidium bromide (EtBr)-stained 
agarose gel electrophoresis. Then, the amplified DNA products were purified using a 
QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) as per the manufacturers’ 
instructions. DNA yield and quality was checked using a NanoDrop spectrophotometer 
and/or agarose gel electrophoresis as required. When double bands were observed in the gel 
electrophoresis, an additional purification step was employed through QIAquick Gel 
Extraction Kit (Qiagen, Hilden, Germany) before proceeding to the genotypic analysis.  
4.4.5 DNA sequencing  
DNA sequencing was performed using three assays: PBSS, NGS, and near full-length 
genome (NFLG) as follows: 
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4.4.5.1 Population-based Sanger sequencing (PBSS) 
As part of Paper II and Paper IV, the purified DNA products were sent to Eurofins MWG 
operon (MWG operon, Germany) for sequencing with four primers: JA204F-C, JA205R-C, 
PR2R, and RT07. Similarly, for Paper III, sequencing was performed using two primers: 
ES7-2F and ES8-2R. 
4.4.5.2 Next-generation sequencing (NGS)  
As part of Paper II, NGS was performed as described earlier [181]. Briefly, a fragment of 
gag-pol region was amplified, gel purified, and fragmented on the Coveris S200 followed by 
library preparation using NEBNext UltraTM DNA library Prep Kit. Forty-eight libraries were 
then pooled at equimolar (10 nM each) and run on Illumina HiSeq 2500. 
4.4.5.3 Near full-length genome (NFLG) 
As part of Paper IV, NFLG was performed as described earlier [156] using 23 sequences 
listed in the Table 1 below. 
Table 1. List of primers used PCR amplifications and sequencing. 
Primer ID Sequence (5’→3’) 
HXB2 
Position Application Paper 
JA203F-C   GAAAGACTGTACTGAGAGACAGGC 2058→2081 Amp. Paper II, Paper IV 
JA204F-C TTCAGAGCAGACCAGAGCCAACAG 2135→2158 Amp., seq. Paper II, Paper IV 
JA205R-C TTTTCCCACTAACTTCTGTATATC 3338→3315 Amp., seq. Paper II, Paper IV 
JA206R-C   TTAATCCCTGGGTAAATCTGACTT 3373→3350 Amp. Paper II, Paper IV 
RT07 AAGCCAGGAATGGATGGCCCA 2586→2606 Seq. Paper II, Paper IV 
PR2R GGATTTTCAGGCCCAATTTTTG 2713→2691 Seq. Paper II, Paper IV 
ED5-1F ATGGGATCAAAGCCTAAAGCCATGTG 6556→6581 Amp. Paper III 
ED12-1R AGTGCTTCCTGCTGCTCCCAAGAACCCAAG 7822→7792 Amp. Paper III 
ES7-ET TTRTTAAATGGTAGTATAGC 7002→7021 Amp., seq. Paper III, Paper IV 
ES8-2R CACTTCTCCAATTGTCCCTCA 7667→7647 Amp., seq. Paper III 
5550F AGARGAYAGATGGAACAAGCCCCAG 5550→5574 Amp. Paper III, Paper IV 
9555R TCTACCTAGAGAGACCCAGTACA  9555→9533 Amp., Seq. Paper III, Paper IV 
6433F CYACCAACGCGTGTGTACCCACAGA  6433→6457 Amp., seq. Paper III 
8329R CCCTGCCGGCCTCTATTYAYTATAGAAA 8356→8329 Amp. Paper III 
0682F TCTCTCGACGCAGGACTCGGCTTGCTG 0682→0708 Amp. Paper IV 
0776F CTAGAAGGAGAGAGAGATGGGTGCGAG 0776→0800 Amp., Seq.  Paper IV 
6352R GGTACCCCATAATAGACTGTRACCCACAA 6352→6324 Amp.  Paper IV 
6231R CTCTCATTGCCACTGTCTTCTGCTC 6231→6207 Amp., seq.  Paper IV 
5861F TGGAAGCATCCRGGAAGTCAGCCT 5861→5884 Amp., seq. Paper IV 
G1231F TCACCTAGAACTTTRAATGCATGGG 1231→1255 Seq. Paper IV 
E30 GTGTACCCACAGACCCCAGCCCACAAG 6445→6471 Seq. Paper IV 
G100F TAGAAGAAATGATGACAG 1817→1834 Seq. Paper IV 
3885R CTGCTCCATCTACATAGAA 3885→3867 Seq. Paper IV 
RTR2 CACAGCTAGCTACTATTTCTTTTGC 4350→4326 Seq. Paper IV 
VIF1F GGGTTTATTACAGGGACAGCAGAG 4900→4923 Seq. Paper IV 
Rev11 ATCATCACCTGCCATCTGTTTTCCAT 5066→5041 Seq. Paper IV 
E70 GGGATCAAAGCCTAAAGCCATGTGTAA 6559→6585 Seq. Paper IV 
E120 GTAGAAATTAATTGTACAAGACCC 7098→7121 Seq. Paper IV 
V3R GAAAAATTCTCCTCYACAATTAAA 7373→7350 Seq. Paper IV 
E160 GTGGGAATAGGAGCTGTGTTCCTTGGG 7761→7787 Seq. Paper IV 
E75 GCGCCCATAGTGCTTCCTGCTGCTCCC 819→7793 Seq. Paper IV 
E230 AATATTCATAATGATAGTAGGAGG 8273→8296 Seq. Paper IV 
E15 CTCTCTCTCCACCTTCTTCTTC 8445→8424 Seq. Paper IV 
LTRF2 GCTTCTACGCGTAAGAAAAGGGGGGACTGGA 9059→9089 Seq. Paper IV 
9181R GTGTGTAGTTCTGCCAATCAGGGAA 9181→9157 Seq. Paper IV 
Amp.: amplification; seq.: sequencing 
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4.4.6 Bioinformatics analysis 
4.4.6.1 Sequence analysis 
The sequences generated with PBSS assay were aligned, and manually edited using BioEdit 
software version 7.2.6.1 available at: http://www.mbio.ncsu.edu/bioedit/bioedit.html. For 
Paper III, the V3 loop sequence was generated using a gene cutter program available at: 
http://www.hiv.lanl.gov/content/sequence/GENE_CUTTER/cutter.html.  
For the NGS analysis FASTQ file was demultiplexed and a consensus sequence was created 
for each sample followed by realignment again with the consensus sequence as input. The 
variant calling was performed at amino acid level. Only amino acid covering 5000X per 
position was considered quality passed. 
For the NFLG assay, sequence analysis was performed in such a way that a multiple 
sequence alignment was generated with the reference genome in AliView version software 
1.17.1 as described earlier [182] and analysed with an in-house Perl script that recognised the 
nucleotide changes from the reference sequence and created a corresponding number code as 
per HXB2 coordinates (HXB2 reference position 790 to 9417). The resulting matrix was 
plotted using the TraMineR package [183] in R ver. 3.1.2 [184] to obtain a diversity plot.  
Maximum likelihood phylogenetic analysis was performed using Molecular Evolutionary 
Genetics Analysis software version 7 (MEGA 7). 
4.4.6.2 HIV subtyping 
HIV-1 subtyping was performed using three different online tools: Recombinant 
Identification Programme (RIP, http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html), 
REGA HIV-1 Subtyping Tool ver. 3.0 (http://dbpartners.stanford.edu:8080/ 
RegaSubtyping/stanford-hiv/typingtool), and COMET HIV-1 (http://comet.retrovirology.lu). 
4.4.6.3 HIV-1 drug resistance test and identification of amino acid mutations 
The mutations considered were for drug classes NRTI, NNRTI, and PIs. In addition, 
mutations associated with INSTIs drug class were considered in Paper II for the baseline 
samples analysed with the NGS assay.  
In Paper II, for the baseline samples analysed by PBSS and NGS assays, surveillance drug 
resistance mutations (sDRM) were identified by the calibrated population resistance tool 
(http://cpr.stanford.edu/cpr.cgi) at Stanford HIVDR Database and using the WHO list of 
DRM for surveillance of TDR. In addition, for the INSTIs associated DRM, the Stanford 
drug resistance summaries for INSTIs (hivdb.stanford.edu).  
In Paper II and Paper IV, acquired DRMs were identified by the Stanford HIVdb 
Programme (hivdb.stanford.edu). Genotypic drug resistance defined as the presence of one or 
more major amino acid substitution included in the 2017 IAS mutation list [185] and the 
Stanford algorithm was used to predict drug susceptibility.  
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For samples analysed with the NGS assay, mutations with frequencies of 1% or more were 
considered for DRM interpretation. In the NFLG assay, the amino acid changes at HIV-1 
gag, pol, vif, vpr, tat, vpu, and nef genomes in month 6 samples as compared to their 
corresponding baseline were manually identified using AliView ver 1.17.1 and BioEdit ver 
7.2.6.1 softwares. 
4.4.6.4 Genotypic tropism testing (GTT) 
In Paper III, GTT was employed to determine viral tropism. Co-receptor tropism was 
predicted from the V3 loop using Geno2Pheno clonal and clinical algorithms as described 
earlier [186, 187]. The Geno2Pheno with false positive rate (FPR) set to 10% and 5% were 
used to determine GTT. The clinical model includes clinical data with nadir CD4 count and 
viral load, to improve the GTT prediction among ART naïve patients. A virus was considered 
X4-tropic or R5-tropic, if all amino acid sequences were predicted. A virus that contained 
both type of amino acid sequences was assigned as mixed R5 and R4 (R5/X4-tropic). The 
Geno2Pheno interpretations include X4-tropic if all translations of a sequence displayed FPR 
≤10%; R5-tropic if FPR >10%; or R5/X4-tropic if sequence translations from a given patient 
displayed FPR ≤10% and >10%. The Geno2PhenoFPR10% tool was used for prediction of 
the virus tropism from the V3 loop sequences of the paired samples generated by the NFLG 
assay in Paper IV.  
4.4.6.5 Statistical analysis  
Overall socio-demographic, clinical, and laboratory parameters were summarized using 
descriptive statistics including mean, median, standard deviation, and percentiles for 
numerical variables, whereas frequencies and percentages for categorical variables. The 
variables analysed include: study site, gender, age, educational status, employment status, 
marital status, spouse HIV sero-status, functional status, WHO clinical stage, TB, OI, ART 
regimen, BMI, weight, CD4 cells, CD4/CD8 ratio, and VL. Differences between categorical 
variables were tested using Chi-square test or Fisher’s Exact Test. Differences in numerical 
variables between two or more categories were tested with independent t-test, Mann-
Whitney, Anova and Kruskal-Wallis. Multivariable logistic regression models also were 
developed in relation to Paper I – Paper III. Odds ratios (OR) with the 95% confidence 
intervals (CI) were presented. P-value <0.05 was considered statistically significant. Data 
analysis was performed using STATA software 14 (Stata Corp. College Station, Texas, 
USA). 
In Paper I, a total of four multivariable logistic regression models were used to identify 
baseline predictors of treatment failure and LTFU at month 6 and 12. Study site, gender, age, 
educational status, employment status, marital status, spouse HIV sero-status, functional 
status, WHO clinical stage, TB, OI, ART regimen (NRTI or NNRTI), BMI, weight, CD4 
cells, CD4/CD8 ratio, and VL were considered as potential predictors of treatment outcome. 
Both stepwise forward and backward methods in multivariable logistic regression models, 
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testing variable with p-value <0.1 in the bivariate analysis were used to select variables 
included in the best final models. 
In Paper II, the impact of sDRM on treatment outcome during the follow up period was 
investigated with a multivariable logistic regression model adjusted for different confounding 
factors. In Paper III, multivariable logistic regression models also were used for analysis of 
virological responses to compare differences between R5-tropic and X4-tropic viruses 
infected patients, adjusting for different confounders. In Paper IV, treatment outcomes were 
compared between patients with different NRTI regimens and the prevalence and type of 
DRMs were compared between patients with TDF- or ZDV-based regimens by Chi-square or 
Fisher’s exact test. 
4.5 ETHICAL CONSIDERATIONS  
Scientific and ethical approvals were obtained from the National Research Ethics Review 
Committee in Ethiopia (3.10|528|06) and the Institutional Review Board (IRB) of Ethiopian 
Health and Nutrition Research Institute (E.H.N.R.I 6.13|163 and E.H.N.R.I 6.13|164).  
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5 RESULTS 
A total of 874 ART naïve individuals were enrolled into the first large countrywide HIV-1 
cohort established at seven hospitals in Ethiopia, where 112 to 134 participants were recruited 
per site. The data and plasma specimens generated were analysed via studies included in the 
four different papers incorporated in this thesis. The thesis mainly studied predictors of the 
treatment outcome and LTFU (Paper I); prevalence and patterns of surveillance- and 
minority-DRM (Paper II); molecular characteristics of co-receptor tropism in HIV-1C 
(Paper III); and acquired DRM and viral genome wide amino acid changes in relation to the 
ART outcome (Paper IV). Summaries of the main findings of the studies addressed in each 
paper are given below. 
5.1 BASELINE PREDICTORS OF ANTIRETROVIRAL TREATMENT FAILURE 
AND LOST TO FOLLOW UP IN A MULTICENTER COUNTRYWIDE HIV-1 
COHORT STUDY IN ETHIOPIA (PAPER I) 
Four multivariable logistic regression models were developed using the data collected from 
the 874 HIV-1 infected patients at baseline, month six and 12 after ART initiation. The 
details of socio-demographic characteristics, clinical and laboratory findings at baseline are 
presented in Table 1 (Paper I). Briefly, the majority of the participants (60%, 527/874) were 
females; median age 33 years (IQR: 28 – 39 years); one-fourth of the participants had TB co-
infection; 38% had one or more OIs and/or AIDS-defining conditions; mean CD4 count was 
144 cells/l (SD: 87); three-fourth of  the participants had below 200 cells/l; and mean HIV-
1 RNA load was 5.2 log10 copies/ml (SD: 0.8). 
5.1.1 Treatment outcome  
Among the 874 patients enrolled into the cohort, 743 (85%) and 690 (79%) reached their 6 
and 12 months follow up period, respectively. On the other hand, 131 (15%) and 184 (21%) 
were LTFU, respectively. Confirmed death accounted for 62 (47%) and 75 (41%) of the 
LTFU at the respective time points. Among 676 and 459 patients with available VL data at 
month 6 and 12 after initiation of ART, the OT analysis identified 57 (8%) and 34 (7%) 
virologic failure patients (VL ≥1000 copies/ml), respectively. Hence, in the ITT analysis, the 
respective treatment failure rates were 23% and 34%. Details of the cohort status during the 
one year ART period with the subsequent treatment outcome is outlined below in Figure 3. 
  43 
 
Figure 3. Advanced Clinical Monitoring of Antiretroviral Therapy in Ethiopia (ACM) cohort 
profile and treatment outcome during the one year treatment follow up period. 
5.1.2 Baseline predictors of treatment failure  
In a multivariable logistic regression model developed at month 6, the odds of treatment 
failure was predicted by gender, TB, OI, CD4 count, VL and study site. At month 12, by 
functional status, TB, CD4 count and study site. In brief, TB co-infected patients had nearly 
twice higher odds of treatment failure than TB negative participants both at month 6 (OR: 
1.75; 95% CI: 1.23 to 2.50) and month 12 (OR: 1.81; 95% CI: 1.25 to 2.61). Patients who 
started ART with CD4 count below 50 cells/µl had nearly three times higher odds of 
treatment failures at month 6 (OR: 3.0; 95% CI: 1.77 to 5.07) and month 12 (OR: 2.54; 95% 
CI: 1.49 to 4.30) than those who started the treatment with over 200 cells/µl. The details of 
the baseline predictors included in the multivariable logistic regression models for treatment 
failure are presented in Table 2 (Paper I). 
Study participants from some regional hospitals such as Harrar, Hawassa, and Mekelle had 
much higher odds of treatment failure at month 12 (OR: 3.89, 95% CI: 2.04 to 7.39; OR: 
2.75, 95% CI: 1.53 to 4.94; OR: 2.01, 95% CI: 1.11 to 3.64, respectively) than those from the 
national tertiary level hospital TASH. The proportions of treatment failure from these 
hospitals were also found to be significantly higher: 41% from Harrar, 45% from Hawassa 
and 37% from Mekelle compared to 24% from TASH.  
5.1.3 Baseline predictors of LTFU  
Likewise, a multivariable analysis identified functional status, WHO stage, CD4 cell count 
and study sites as predictors of LTFU at month 6. At month 12, gender, functional status, 
WHO stage, TB, CD4 cell and study site were predictors of LTFU. Briefly, patients with 
functional disabilities had higher odds of LTFU (OR: 2.37; 95% CI: 1.54 to 3.63 for 
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ambulatory patients; OR: 2.22; 95% CI: 0.86 to 5.71 for bedridden patients at month 6 and 
OR: 2.20; 95% CI: 1.49 to 3.24; OR: 3.63; 95% CI: 1.61 to 8.18 at month 12) as compared to 
those who had working functional status at ART initiation. Patients with advanced WHO 
clinical stage had nearly twice higher odds of LTFU (OR: 1.79; 95% CI: 1.21 to 2.37 at 
month six and OR: 1.92; 95% CI: 1.36 to 2.72 at month 12) compared to those with early 
WHO clinical stage I/II.  Patients who started ART with lower CD4 count such as below 50 
cells/µl had higher odds of LTFU (OR: 2.32; 95% CI:  1.28 to 4.19 at month 6 and OR: 2.65; 
95% CI: 1.57 to 4.46 at month 12) compared to those started with over 200 cells/µl. TB co-
infected patients also had higher odds (OR: 1.97; 95% CI: 1.37 to 2.84) of LTFU at month 12 
compared to TB negative participants. Details of the multivariable logistic regression models 
for the LTFU both at month 6 and 12 are presented in Table 3 (Paper I).  
Again, participants from regional hospitals such as Harrar, Hawassa and Gondar had higher 
odds of LTFU (OR: 2.75, 95% CI: 1.30 to 5.81; OR: 2.39, 95% CI: 1.12 to 5.07; OR: 2.25, 
95% CI: 1.06 to 4.80 at month 6; and OR: 2.20, 95% CI: 1.17 to 3.13; OR: 2.16, 95% CI: 
1.15 to 4.06; OR: 1.83, 95% CI: 0.97 to 3.47 at month 12, respectively) compared to TASH. 
Higher proportions of LTFU were identified from Harrar (27%, and 51%), Hawassa (20%, 
and 38%), and Gondar (19%, and 29%) compared to TASH (10%, and 17%) at month 6 and 
12, respectively. Comparative proportions of the treatment failure and LTFU across the study 
sites are presented on Figure 2 (Paper I). 
5.2 PRETREATMENT DRUG RESISTANCE IN A LARGE COUNTRYWIDE 
ETHIOPIAN HIV-1C COHORT: A COMPARISON OF SANGER AND HIGH-
THROUGHPUT SEQUENCING (PAPER II) 
The prevalence and patterns of surveillance- and minority-DRM at ART initiation were 
determined using PBSS and NGS assays. The detected sDRM by the two assays were 
compared and the impact of TDR on first-line ART outcome was also evaluated. In addition, 
INSTI associated DRM were identified by NGS assay. The details of patients’ baseline 
characteristics included in the two assays are presented in Table 1 (Paper II). 
5.2.1 sDRM detected by PBSS 
The PBSS assay was attempted on baseline plasma samples derived from 490 randomly 
selected patients after stratifying those with available samples by study sites (70 from each 
site). Of the 490 samples, the pol-gene was successfully sequenced for 461 (94%) and all 
sequences clustered within HIV-1C, except one CRF02_AG. Of the 461 sequences, sDRM 
was detected in18 (3.9%) including nine NRTI-, seven NNRTI-, and two PI- associated 
resistance mutations. No sample found with dual class sDRM, but three were found to have 
double mutations from the same ARV drug class. Among the baseline parameters tested for 
their association with the detected sDRM, only participants’ age (OR: 0.93; 95% CI: 0.87–
0.99) and viral load (OR: 2.67; 95% CI: 1.25–5.71) found to have significant correlation. The 
details of the sDRM detected by the PBSS assay and the study profile are presented in Table 
2 and on Figure 1 (Paper II), respectively.  
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Considering the WHO virologic failure definition (VL >1000 copies/ml) and using the OT 
analysis, those patients with RTI- sDRM had higher odds of treatment failures after 6 and 12 
months of ART than those without such mutations (OR: 9.0, 95% CI: 1.9–43.3 and OR: 7.4, 
95% CI: 1.5–35.0 adjusted for tuberculosis co-infection, respectively). In the ITT analysis, 
those with RTI- sDRM had nearly four times higher odds of treatment failures at month 6 
than those without the mutations (OR: 3.8, 95% CI: 1.4–10.5), but no significant association 
was found at month 12.  
5.2.2 DRM detected by NGS  
The NGS assay was performed on 109 selected baseline samples derived both from patients 
who had detectable viremia at month 6 and/or month 12 (n=71) and undetectable viremia 
(n=38). All of the 109 baseline samples were successfully sequenced and DRM (with 
mutation frequency >1%) was detected in 28 (25.7%) patients; 23 from the virologic failure 
patients, and five from the virologic suppressors. The NGS assay detected DRMs associated 
with one to three different classes of ARVs including NNRTIs alone in ten sequences; NRTIs 
in eight, PIs in three; INSTIs in two; NRTI and NNRTI in one; NRTI and PI in one; NRTI 
and INSTI in one; and three drug classes (NRTIs,  PI and INSTIs) in two sequences. In 
addition to the RTI- and PI- sDRM, the NGS assay detected major INSTI-DRMs in minor 
viral variants from five patients including E138K (n=2), Q148R, Q148H, and T66I.  
5.2.3 Comparative analysis of the sDRM detected by NGS vs PBSS 
The NGS assay detected RTI- or PI- associated sDRM more frequently than PBSS (23.9%; 
26/109 vs 6.4%; 7/109; p<0.0001). Again, when only the RTI-sDRM from virologic failures 
was separately considered, the NGS detected the mutations more frequently than the PBSS 
assay (28.2%, 20/71 vs 8.54%, 6/71; p=0.004). The odds of detection of RTI- and/or PI- 
associated sDRM by NGS was higher among patients with detectable viremia at month 6 
and/or 12 as compared to those who had undetectable viremia (OR: 6.4; 95% CI: 1.6 – 26.4 
adjusted for NRTI regimens and CD4 cells). Details of the DRM detected by NGS are 
presented in Table 3 (Paper II). 
5.3 MONOPHYLOGENETIC HIV-1C EPIDEMIC IN ETHIOPIA IS DOMINATED 
BY CCR5-TROPIC VIRUSES-AN ANALYSIS OF A PROSPECTIVE 
COUNTRY-WIDE COHORT (PAPER III) 
A randomly selected 420 baseline samples (60 from each site) was attempted for PBSS 
analysis of the V3 loop, and successful sequences were obtained from 352 (84%). The V3 
loop was also successfully sequenced from 34 and 19 samples of virologic failure patients at 
month 6 and 12, respectively. Additionally, 387 historical sequences of the HIV-1CET V3 
loop (archived from Ethiopia during 1984 – 2003) were obtained from the Los Alamos HIV 
Sequence Database for comparison with our sequences. Of the 352 successful baseline 
sequences, 350 (99.4%) clustered to HIV-1C and the reaming two assigned as subtype A1. 
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5.3.1 Genotypic tropism testing (GTT) 
Of 352 V3 loop sequences generated from the baseline samples, the Geno2PhenoFPR10% 
clinical model predicted R5 in 285 (81%); X4 in 60 (17%); dual R5/X4 in 7 (2%) sequences. 
The Geno2PhenoFPR10% clonal model also predicted R5 in 291 (83%); X4 in 50 (14%); and 
dual R5/X4 in 11 (3%) sequences. Overall, the X4-tropic strains were present in 107 (30%) 
by any of the two GTT models, where only 21 (6%) were pure X4-tropic strains by both 
models. Of the parameters tested at baseline, CD4 count found to have significant association 
with the virus tropism predicted by the clinical model (p < 0.001), but not by the clonal 
model. When Geno2PhenoFPR5% was used, X4-tropic strains were predicted in 47 (13.3%) 
sequences by any of the models. The virus tropism had significant association with CD4 
count by both models (p = 0.001 and p = 0.023 by the clinical and clonal models, 
respectively). Details of the tropism predictions are presented in Table 2 and on Figure 2 
(Paper III). 
The Geno2PhenoFPR10% comparative analysis of the historical sequences with ours revealed 
that the proportion of X4- and dual R5/X4-tropic strains increased in Ethiopia over time from 
5.6% in 1984 – 1993, to 7.1% in 1994 – 2003, and to 17.3% in 2009 – 2011 (p<0.001).  
5.3.2 Impact of baseline tropism on treatment outcome 
The Geno2PhenoFPR10% clonal model predicted R5 in 29 (85%) and X4 or dual X4/R5 in five 
(15%) of the 34 sequences from month 6 samples. A 7% (2/29) and a 40% (2/5) tropism 
switch were observed in the respective groups and the difference in the virus tropism switch 
was statistically significant (p= 0.006). At month 12, R5 was predicted in 15 (79%) and X4 or 
R5/X4 in four (21%) of the 19 V3 loop sequences. Only three of the later four X4 containing 
viruses switched from R5, but the difference was not statistically significant. In addition, the 
multivariable analysis could not find significant differences in treatment outcome between 
patients with X4-tropic and R5- tropic virus. 
5.4 HIV DRUG RESISTANCE AND GENETIC DIVERSITY AMONG PATIENTS 
FAILING FIRST-LINE THERAPY IN THE FIRST LARGE COUNTRYWIDE 
ETHIOPIAN HIV COHORT ASSESSED BY SANGER- AND NEAR-FULL 
LENGTH SEQUENCING (PAPER IV) 
Treatment outcomes and emergence of HIV DRMs and amino acid changes among virologic 
failure patients after 6 and 12 month of ART were described. OT and ITT analyses were 
performed on data collected from the 874 patients who had received first-line ART regimens 
including TDF, 467; ZDV, 362; d4T, 44; and ABC, one patient. However, there was no 
statistically significant difference in treatment outcome (both by OT and ITT analysis) across 
the NRTIs. Prevalence and patterns of acquired DRM and amino acid changes were 
described using PBSS and NFLG assays. The details of patient baseline characteristics 
included in the different studies and the treatment outcome across the NRTIs were presented 
in Table 1 and Table 2, respectively (Paper IV).   
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5.4.1 Acquired DRM detected by PBSS 
Of the 57 month 6 samples attempted for PBSS assay, 47 were successfully sequenced from 
28/34 (82.6%), 15/19 (78.9%), and 4/4 (100%) patients who failed TDF-, ZDV-, d4T-based 
first-line ART regimens, respectively. Major DRMs associated with RTIs were detected in 36 
(76.6%) samples including 21 from TDF- and 12 from ZDV-failure patients. The DRM 
detected in the 21 TDF failures include 17 NRTI+NNRTI; and four NNRTI alone. Ten 
(35.7%) patients had K65R. The DRM among 12 ZDV failures include five NRTI+NNRTI; 
six NNRTI alone, and one NRTI only). No K65R was found from patients who received 
ZDV-based regimens.  
Likewise, of the 33 month 12 samples attempted for PBSS analysis, 30 were successfully 
sequenced from 16/17 (94.1%), 10/12 (83.3%) and 4/4 (100%) patients who failed TDF-, 
ZDV-, d4T-based regimens, respectively. Major RTI-DRMs were found in 20 (66.7%) 
samples including 13 from TDF- and five from ZDV- failure patients. The DRM detected 
among the 13 TDF failures include 12 NRTI+NNRTI; and one NNRTI alone. Half of the 
TDF failure patients had K65R. The DRM found among ZDV failures include two 
NRTI+NNRTI; two NNRTI alone; and one NRTI alone. At month 6, no difference was 
found between TDF- and ZDV- failing patients with regard to the number of RTI-DRMs. 
However, at month 12 sequences from TDF-failure samples had more DRM associated with 
RTI than those from ZDV-failures (p= 0.017), and also when stratified by drug class 
including NNRTI-DRM (p= 0.037), and NRTI-DRM (p= 0.040). List of the DRM per patient 
and the details of DRM across NRTIs were given in Supplementary Table S1 and Table 3, 
respectively (Paper IV). 
5.4.2 Amino acid changes identified by NFLG  
Amino acid changes during the first six months of ART were analysed using NFLG assay, 
which generated successful sequences on HIV-1 gag, pol, vif, vpr, tat, vpu, and nef genomes 
from 32 (16 paired baseline and month 6) samples. In addition, the env (V3 loop) region was 
successfully sequenced in 13 baseline and 14 month 6 samples for analysis of co-receptor 
tropism. The LTR region was also successfully sequenced in all of the 32 samples for 
analyses of the NF-kB.  
Analysis of the pol gene revealed that 11 (68.8%) patients had acquired one to five (median: 
three) major DRMs associated with RTIs after six months of ART including seven associated 
with NRTI+NNRTI; and four with NNRTI. Although none had known PI- or INSTI- DRMs, 
several other mutations were identified in the PR and IN regions. Four amino acid insertions 
(GLIP/GALN/GTLV/GALN) were also displayed at positions 48 – 55. The predicted 
sensitivities to N/NRTI were presented on Figure 2 (Paper IV). 
Analysis of the gag gene showed that amino acid changes mostly clustered in the p6 and p17 
regions. In the Gag-p6 region, frequent mutations and insertions were found. For example, 
PYKE insertion was found in nine (56.3%) of the 16 paired samples. In addition, duplicate 
tetra-peptide motif PTAP was identified in two samples at baseline, where the respective 
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month 6 samples had single motif (deletion of one of the double motifs). A triple PTAP tetra-
peptide motif was also identified from paired samples of one patient. R4S mutation was 
identified in 14 (87.5%) patients at the C-terminal of p17. A number of mutations were also 
identified in the vif and nef genes. On the other hand, the tat, vpu and vpr genes showed very 
few amino acid changes. Detail representation of the amino acid changes in the different 
genomic regions are presented in Figure 3 (Paper IV). 
The Geno2PhenoFPR10% tool predicted R5 in 10 (77%) and 12 (86%) of the 13 and 14 baseline 
and month 6 V3 loop sequences, respectively. The two X4 and one R5/X4 dual tropic viruses 
found at baseline switched to R5 and X4, respectively. Of the 16 samples, 15 (94%) 
displayed three nuclear factor kappa B (NF-kB) each in the enhancer region of the LTR of 
HIV-1C. Whereas, one sample shows large insertions and four instead of two binding sites 
after 6 months of ART. 
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6 DISCUSSIONS 
For more than a decade, ART has been widely and rapidly scaled up in Ethiopia through the 
WHO public health approach and the treatment coverage is reported to have reached 60% 
among PLHIV [76]. However, the overall health care system is inadequate to meet the 
complex monitoring standard required by the ART service such as viral load and GRT. 
Besides, a high rate of LTFU has been reported [44, 166]. All this contributes to a high rate of 
late diagnosis of treatment failure patients with subsequent emergence and accumulation of 
drug resistance as reported also from other sSA [91]. However, data is not earlier available 
from Ethiopia, at least at the national level. In addition, even if HIV-1C was discovered in 
Ethiopia [3], the distribution of subtypes has not been characterised at a countrywide level.  
Previous studies have had a limited geographical coverage, representing mainly the capital 
Addis Ababa and Northwest part of the country. Thus a clear picture of the epidemic in the 
country had not earlier been provided. Therefore, in view of filling the abovementioned 
research gaps, I have performed the studies included in this thesis using a countrywide HIV-1 
cohort. A total of 874 ART naïve individuals were enrolled in this HIV-1 cohort established 
at seven hospitals in Ethiopia, where 112 to 134 participants were recruited per site. The 
cohort had a good geographical distribution, which should represent the national HIV 
epidemic profile for the first time. In addition, among the 874 patients enrolled, 743 (85%) 
and 690 (79%) reached their 6 and 12 months follow up time point, respectively. The GTR 
study conducted certainly met the WHO recommendation mentioned in its “2012 Global 
Strategy for the Surveillance and Monitoring of HIV Drug Resistance [188],” to conduct 
cross-sectional surveys of acquired HIVDR at nationally representative university affiliated 
hospital ART clinics. Therefore, the findings described in my thesis most likely reflect the 
status of the ART outcome including LTFU and death; drug resistance both PDR and ADR; 
and the HIV-1C epidemic at the national level. The main findings from each paper are 
discussed below:- 
In Paper I, we found that the virologic failure rate as determined by OT analysis (VL >1000 
copies/ml) was below 10% both at month 6 and 12. This was comparable with earlier reports 
from other sSA studies [189, 190]. The result was in harmony with the last 90 in the 
UNAIDS 90-90-90 ambitious strategy [122]. However, in the ITT analysis (VL >1000 
copies/ml plus LTFU including death), the treatment failure rate was substantially higher, 
23% and 34%, at month six and 12, respectively. Although this was also comparable with 
reports from other sSA [191-193], it was substantially lower than the retention rate targeted 
by the UNAIDS 90-90-90 strategy. The study identified early mortality and LTFU as the 
main reasons for poor ART outcome in Ethiopia, as reported from other sSA countries [194]. 
The early mortality and the low CD4 T-cell counts at diagnosis also clearly indicate that the 
proportion of PLHIV who know their status is very much lower than the first 90. This suggest 
a need for continued supportive efforts in order to reduce early mortality and LTFU in the 
ART programme but also to diagnose patients at a much earlier phase of infection. 
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We developed four multivariable models, which identified male sex, functional disabilities, 
advanced WHO clinical stages, TB and other OIs, low CD4 cell count, and high VL as 
baseline predictors associated with increased odds of viral failure and/or LTFU at month 6 
and 12. Of course, this has already been described in previous studies done in other LMIC. 
However, the design of this multisite countrywide HIV-1 cohort allowed us to identify study 
site as one of the strongest predictors of ART outcome in Ethiopia. Regional differences in 
the prevalence of sexually transmitted infections and variations with regard to knowledge 
towards HIV prevention have previously been reported in Ethiopia [195]. In the present 
study, we have for the first time identified significant regional differences in ART outcome in 
the country. This may be attributed to socio-demographic and socio-cultural variations along 
with cultural and religious practices within different parts of the country, although the design 
of the cohort did not allow us to study this. In view of the ART outcome differences observed 
across the hospitals, we recommend provision of additional support to strengthen capacity of 
the regional health care system. 
Due to deficiencies in the health care systems, the rapid scale-up of ART in LMIC has raised 
concerns for enhanced accumulation of PDR and its onward transmission to newly infected 
patients [196]. The PDR rate has recently been reported to increase in the African region. 
However, there are only few studies showing the pattern and prevalence of PDR in Ethiopia 
and these studies have had limited geographical coverage, lacking continuousness and the 
national prevalence has remained to be determined. Therefore, using the countrywide HIV-1 
cohort, prevalence and patterns of PDR were studied in Paper II by employing both PBSS 
and NGS assays. The respective assays detected 3.9% and 25.7% DRM rates, among 461 and 
109 baseline samples of ART naïve patients. The prevalence detected by the PBSS assay was 
low, especially when considering the recently observed increased rates of PDR in the East 
African regions [77]. It was also below the WHO threshold for surveillance of TDR. 
However, it should be noted that the samples analysed in this study were collected during 
2009 – 2011 and the current TDR prevalence rate may have been changed. 
Further, considering the fact that majority of the participants had low CD4 cell counts, they 
can be classified as late presenters. Consequently, the TDR rate might have been 
underestimated by the PBSS assay since some drug resistant variants frequently disappear 
from the major viral population, especially during the period when ART is not initiated [77]. 
Hence, we also determined the baseline DRM by the robust NGS assay with capacity of 
detecting mutations also in the minor population (>1% frequency), where the PDR 
prevalence was found to be 25.7% in our study. Although the samples were not randomly 
selected and there could be a sample selection bias, our baseline DRMs prevalence detected 
by the NGS assay was supported by the recently observed increasing trends in East Africa 
[77].  
Since the rollout of ART a temporal increasing trend of TDR has been observed across the 
few available scattered reports from Ethiopia including <5% from Addis Ababa in 2005 
[175]; 5.6% from Gondar, Northwest Ethiopia in 2008 [177]; and 7.2% again from Gondar in 
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2010 [197]; all studies were done with Sanger-based assays. Effects of PDR on the virologic 
outcome and emergence of DRM among treated patients have been previously reported from 
sSA [98]. The observed increasing trend could compromise the effectiveness of the few 
available first-line ART regimen options in the region thereby also limit the clinical benefits 
from ART. Hence, genotypic resistance screening would be essential at ART initiation. 
Nevertheless, subsequent studies on samples collected from newly infected individuals are 
recommended to ascertain the current magnitude of TDR in Ethiopia.  
In our comparative analysis NGS detected a higher rate of sDRM than PBSS. Additional 
baseline DRMs were detected from 17 patients selected for the NGS, which was consistent 
with an earlier report of a high detection rate of NNRTI- TDR by an allele-specific PCR (AS-
PCR) (6.5%) in Addis Ababa, performed by our group [134]. The discrepancy between our 
PBSS and NGS assays suggests that NGS could facilitate detections of sDRMs in LMIC by 
the same or lower costs if high-throughput assays are used and could therefore be an 
alternative method for screening surveillance of TDR/PDR [198]. 
With the NGS, we also identified major DRMs associated with INSTIs in five ART naïve 
individuals, including T66I, E138K, Q148R, and Q148H. These DRMs alone or in 
combinations associated to different levels of RAL and/or EVG resistances [72]. Although 
INSTIs are planned to be integrated in the ART regimen in some African countries, they are 
not part of the treatment strategy in Ethiopia so far neither is an approval of its use in the 
country documented. However, it is not unlikely that the second-generation INSTI, such as 
DTG and BIC, will become valid alternatives also in Ethiopia since the cost is now becoming 
dramatically lower, as compared to HIC. 
In addition, with maximum likelihood phylogenetic analysis, we confirmed that there was no 
clustering across the samples harboring the INSTI associated DRMs (Figure 2). Patients 
whose baseline samples harboured the INSTI-DRM were from five different geographically 
distinct hospitals, where possible transmission of the INSTI-resistant viral variants was less 
likely. Thus, wild type HIV-1C strains might harbor low abundance of INSTI-DRMs in 
Ethiopia. However, potential clinical impacts of the detected DRMs still remain to be 
evaluated because some studies reported that low abundance of INSTI-DRMs had no effect 
[199, 200]. These circumstances warrant further studies on INSTI-DRMs in the minor virus 
population in Africa and elsewhere, where some countries plan to deploy the use of DTG in 
the near future. 
In Paper III, we assessed the HIV-1 subtype distribution across the different parts of 
Ethiopia through sequencing and analyzing the env gene. Of the 352 successful sequences, 
350 (99.4%) clustered to HIV-1C, which was consistent with previous reports. Since its first 
identification in Ethiopia in 1986 [3], HIV-1C has consistently been reported as the 
predominant subtype in the country. For example, studies conducted in the mid- and late-
1990s mostly among commercial sex workers and pregnant women in Addis Ababa using the 
env gene identified HIV-1C in 98.5% to 100% [36, 201, 202]. Later studies from Gondar, 
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Northwest Ethiopia, using gag-pol and pol sequences also identified HIV-1C in 97.8% [176] 
to 98.7% [177] of the infections. 
Although our study and earlier reports have shown that HIV-1C have monophylogenetically 
dominated (>99%) the epidemic in Ethiopia since its estimated introduction into the country 
in 1970 [203], this situation contradicts with other African countries’ reports, even with the 
neighboring East African, where different HIV-1 subtypes are co-circulating [20]. Studies 
from neighboring countries showed that HIV-1C has been co-circulating with other subtypes 
mostly with subtype A and D. For example, in Djibouti, HIV-1C accounted only for 65.7% of 
the subtypes [204]; in northern Kenya, 27% [205]; in western Kenya, 6% [206]; and in 
Sudan, 30% [207]. HIV-1 subtype A and D together accounted only for <1% of the epidemic 
in Ethiopia, which are likely to have been introduced from the abovementioned neighboring 
countries. 
In this study, we also assessed the distribution of co-receptor tropism at baseline and its 
impact on virologic- and immunologic-treatment outcome after 6 and 12 months of ART. 
Tropism switch after 6 and 12 months of first-line ART was also determined. The 
Geno2PhenoFPR10% clinical model predicted R5-tropic viruses in 81% of the baseline 
sequences generated from the V3 loop; X4 in 17%; dual R5/X4 in 2%. The respective 
predictions by the Geno2PhenoFPR10% clonal model were 83%, 14%; and 3%. Overall, both 
GTT tools predicted that the epidemic in Ethiopia is dominated by CCR5-using HIV-1C 
strains, which is in line with earlier studies involving samples from Ethiopia [208, 209]. 
However, comparative analysis using historical sequences and the sequences generated in our 
study showed a slight temporal increment in proportion of X4- and dual R5/X4-tropic HIV-
1C strains in Ethiopia. This finding is in agreement with other studies done in Botswana 
[210], South Africa [211], and India [212], where increasing trends in X4-tropic HIV-1C 
strains have been documented during the last decade. 
Although studies have shown an effect of the baseline co-receptor tropism on disease 
progression and treatment outcome [213, 214], the multivariable analysis in our study could 
not find such effect. Even if we found too few X4-tropic strains at baseline, a bidirectional 
tropism switch was identified both among month 6 and 12 samples of virologic failures, but a 
switch from X4 to R5 was more common. However, whether this is a common feature of 
HIV-1C is not yet fully understood. 
In Paper IV, we described treatment outcomes in relation to the emergence of HIV drug 
resistance and amino acid changes among virologic failure patients. As discussed in Paper I, 
findings from this countrywide HIV-1 cohort confirmed that early death and LTFU are the 
main reasons for poor treatment outcome in Ethiopia. However, a wide range of DRMs to the 
first-line ART regimens was commonly detected among virologic failures, who had also 
continued the treatment. Up to seven (median three) and eight (median four) HIV-1 DRMs 
were identified per sequence from 76.6% and 66.7% of the virologic failures at month 6 and 
12, respectively. Majority (66.7% and 64.0%, respectively) of the detected DRMs per 
sequence conferred resistance to dual drug classes (NRTIs and NNRTIs).  
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Although the viral pol sequences from earlier studies in Ethiopia are few and the follow up 
time points and viral load cut-off differ from ours, the DRMs rates observed in our study 
were lower than reports from Jimma (81.8%, 9/11) at month six [171] and from Gondar 
(75%, 6/8) at a median time of 30 months on ART [178]. We have also reported a wider 
pattern of NRTI-DRMs as compared to the studies from Jimma and Gondar, where only 
limited types of NRTI associated DRMs were reported. However, the rate of DRMs and 
mutation patterns identified in our study were generally in agreement with a report from a 
multicenter cohort in six sSA countries, where 70% of the sequence from virologic failures 
(after 12 month of ART) harbored DRMs and 49% had dual class (NRTI and NNRTI) 
resistance, with an average of 2.4 DRMs per sequence (range: 1 – 8) [98]. However, the 
average number of DRMs and the proportion of dual class drug resistance observed in our 
study were higher than the sSA multicenter cohort.  
Neither a difference in virologic failure rate nor in DRM rate was observed across the NRTI-
based regimens. The most frequently observed NRTI-DRMs were K65R, M184V/I, and 
TAM, but the K65R mutation was only found among TDF-treated patients. In a recent report 
from Gondar a low frequency of K65R was reported [172]. The DRM patterns we observed 
were relatively in agreement with the multicenter sSA countries cohort, where M184V, 
K65R, and TAMs were the most commonly observed NRTI-DRMs [98]; and a Ugandan 
study, where M184V, K65R, and TAMs were most frequently observed [193]. In contrary, a 
study from Kenya did not report the K65R mutation, but none of their patients took TDF-
based regimens [206]. 
K65 is one of the notable residues due to its pivotal position in the deoxynucleotide 
triphosphate (dNTP)-binding pocket; and its involvement in nucleoside analogue resistance 
and polymerase fidelity [215]. Mutations at the K65 position of HIV-1 RT reduces 
susceptibility of the virus to different NRTIs including TDF, 3TC, FTC, and ABC [216]. 
Studies have also shown that K65R mutation is preferentially selected by HIV-1C in ex vivo 
and in vitro analyses [217, 218]. As per the WHO recommendations, TDF has replaced 
thymidine analogues including ZDV and d4T in first-line ART regimens. The majority of our 
study participants received TDF-based first-line regimens. As described in the background 
section (section 1.5.2.2), studies have shown that TDF–resistant viruses have a substantial 
transmission potential [92, 99-101], and subsequently an increasing prevalence of resistance 
against this drug is an important concern.  
Overall, our findings showed that the main reason or consequence of virologic failure was the 
emergence of drug resistance. The most important factors influencing the emergence of 
HIVDR in sSA include limited treatment options; treatment interruptions due to drug stock 
outs; and poor treatment monitoring strategies, where viral load and GRT are not used to 
monitor the ART outcomes [91, 92, 97]. Our study also pointed out that further expansion of 
TDF in HIV-1C dominated sSA region including Ethiopia, where viral load monitoring is not 
routinely used (at least presently) may result in an extensive spread of the K65R mutation. 
Together with the high potential transmission capacity of K65R strains, the mutant viruses 
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may jeopardize future therapeutic and prophylactic use of TDF and tenofovir alafenamide 
[219]. 
A possible way forward to improve treatment outcome could be the use of long-acting drugs, 
such as the INSTIs cabotegravir, which inhibits HIV-1C at least as efficient as HIV-1B [220], 
and the NNRTI rilpivirine. However, both approaches should be further evaluated by several 
reasons of which one reason might be the presence of major INSTI-DRMs in minor viral 
variants, as identified among five ART naïve patient samples in our cohort [96]. Also 
rilpivirine treatment can be questioned due to the high viral load in the majority of our 
patients at diagnosis and the less binding efficacy of the drug to the HIV-1C reverse 
transcriptase [96, 221].  
In addition to analyses of the pol region by PBSS, we also employed NFLG to describe all 
relevant target regions of HIV-1 for drug resistance. The NFLG analysis was done in 32 (16 
paired baseline and month 6) samples of virologic failure patients. Although the point 
mutations we identified are not known to influence the response to PIs, the NFLG assay 
identified gag mutations in the majority of virologic failures, especially in the p6 and p17 
regions. Gag is essential for virus particle formation and its C-terminal p6 domain harbors 
short peptide motifs that facilitate virus release from the plasma membrane and mediate 
incorporation of the viral Vpr protein. Hence, although the sites and functional relevance of 
Gag-p6 is not completely known, changes in the C-terminal Gag-p6 domain plays important 
role in the release of viral particles [222]. HIV-1C also has unique amino acid frequencies in 
this region. 
We found a PYKE tetra-peptide in the ALIX-binding motif of Gag-p6 in nine paired samples 
(both at baseline and month 6) which remained unaffected by the treatment in all patient 
samples. This tetra-peptide motif was observed also among half of treatment naïve Ethiopian 
patients in our earlier study, but the status was not known among ART experienced patients 
[223]. However, this study identified the PYKE motif only in few sequences from South 
African and Indian ART naïve HIV-1C infected patients (1% and 3%, respectively). 
Therefore, it is important to study the clinical relevance of the PYKE motif in terms of viral 
fitness and susceptibility to ART, especially to PI drugs with a larger number of HIV-1C 
viruses.  
On the other hand, deletion of the PTAP motif in the Gag-p6 was identified in two samples 
(at month 6), which initially had double motifs in their corresponding baseline samples. 
Subtype specific differences have earlier been observed in Gag-p6 with regard to this tetra-
peptide motif [224, 225]. A study also showed a difference in ART outcome in relation to 
duplication of the PTPA motifs including HIV-1C [225].The duplication probably restores 
the ALIX mediated virus release pathway, which is lacking in HIV-1C as PTAP motif is 
thought to be a key player in viral budding [224]. However, the disappearance of the 
duplicated PTPA tetra-peptide motifs in most of our patient paired samples contradicted with 
what has been reported in a study which also included HIV-1C [225]. In addition, to the best 
of our knowledge, so far no study has shown a triple PTPA motif. Therefore, we recommend 
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further studies about the significance of this tetra-peptide motif on treatment outcome and its 
clinical relevance. 
It can also be noted that resistance to DTG has been described outside the integrase, mainly in 
nef and LTR overlapping region in vitro, and in patients failing monotherapy with DTG 
[226]. In contrast to the findings in the gag gene, no common pattern of amino acid changes 
was seen in the other genes, with the exception of known RTI-DRM in the pol gene. 
However, in the NFLG sequences we identified three NF-kB binding regions in the LTR 
which is unique for HIV-1C as earlier described by our group [227]. 
In summary, this thesis presents for the first time major findings on the HIV-1C epidemic and 
the antiretroviral treatment response including the molecular epidemiology of drug resistance 
at a countrywide level in Ethiopia. Our findings from the on-treatment vs intention-to-treat 
analyses pointed out that early LTFU and mortality are outstanding problem in the treatment 
of HIV rather than detectable viremia while being on treatment. The genotypic resistance 
tests by PBSS, NGS, and NFLG detected broad DRMs associated with different ARV drug 
classes including RTIs, PIs, and INSTIs. Our findings also showed that R5-tropic HIV-1C 
monophylogenetically dominate the epidemic, although a temporal slight increasing trend in 
X4-tropism usage observed. Hence, this thesis provides a range of fundamental information 
from the molecular epidemiology of HIV-1C epidemic to its therapeutic responses in 
Ethiopia that could be used by researchers, clinicians, policy makers, and other stakeholders. 
In addition, the thesis is based on one of the largest countrywide HIV-1 cohort in Africa; the 
findings have most likely implications in other HIV-1C dominated countries. 
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7 CONCLUSIONS AND FUTURE PERSPECTIVES 
This thesis provides an account of the HIV-1C epidemic and ART outcome in Ethiopia using 
the first large countrywide HIV-1 cohort, which most likely reflects the national profile 
during the study period. The following specific conclusions and recommendations can been 
drawn from the studies included in the thesis: 
 The on-treatment virologic suppression rate was above the WHO-suggested targets for 
HIV drug resistance prevention, but a high rate of treatment failure was identified by the 
intention-to-treat analysis, reflecting that early death and LTFU are major reasons for 
poor ART outcome in Ethiopia. It is possible that the recently recommended universal 
test and treat strategy could positively contribute in reducing the observed LTFU and 
death rate because the majority of the participants in this study started ART with low 
CD4 cell counts and advanced WHO clinical stages.  
 In addition to well-known determinants such as advanced WHO clinical stages, low CD4 
cell count, TB and other OIs , the study site was found to be a strong baseline predictor of 
treatment failure. Compared to national tertiary hospital located in the capital city, the 
regional hospitals had a higher proportion of treatment failure, which highlights the need 
for provision of more regional support . 
 Our comparative study on sDRM showed that NGS detected a higher rate of TDR as 
compared to PBSS, which underestimates the prevalence of TDR. The NGS also 
identified major INSTI resistance mutations in minor viral variants. However, their 
clinical impact should be confirmed. In addition, our findings highlighted the potential 
value of using high-throughput NGS in surveillance studies of PDR in LMIC. 
 Broad NRTI- and NNRTI-DRMs patterns were identified among three quarters of the 
virologic failure patients who continued the treatment, but there was no significant 
difference with regard to treatment outcome or level of drug resistance between patients 
who were treated with TDF- or ZDV-based first-line ART regimens. This shows the need 
for application of viral load testing and GRT monitoring of ART in LMIC. Our NLFG 
assay amplified efficiently the HIV-1 genes with known or potential relevance for drug 
resistance and is thereby an attractive alternative for surveillance studies in LMIC. 
 CCR5-tropic HIV-1C dominates monophylogenetically the epidemic in all regions of 
Ethiopia despite many years since its introduction, even among patients with very 
advanced disease, though a slight temporal increasing trend of CXCR4-tropic and dual-
tropic strains might have been occurred since the epidemic started.  
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